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INTRODUCTION
“Retroviruses are unique among infectious agents, both in the way they interact with the
host cells and organism and in the consequence of this interaction - not only to the life of
the infected host but also in some cases to the host’s descendants. No other infectious agent
of higher eukaryotes regularly integrates its genetic information into the host genome; no
other regularly acquires host genes into its genome, no other can infect the germ line of its
host; no other has played such an important part in so many aspects of modern biology.”
JM Coffin, SH Huges, and HE Varmus in The Interaction of Retroviruses and Their Host (1997).
I: Brief introduction to retroviruses.
Taxonomy
The replication strategy of any virus depends on the nature of its genetic material. In this
respect, all viruses can be divided into seven groups (“Baltimore Classification”).
Retroviruses, which represent a large group of viruses found in many species, are classified
in the group VI: Viruses with single-stranded (+) sense RNA with DNA intermediate in life
cycle. The family Retroviridae in this group is currently furthered subdivided into seven
genera defined by evolutionary relatedness (Table 1). The first five of these genera
represent viruses with oncogenic potential, and were therefore previously classified into the
subfamily Oncovirinae. According to the International Committee of Taxonomy of Viruses
(ICTV) this classification is no longer appropriate, since these viruses are no more closely
related (or similar) to one another than they are to members of the other previously
designed subfamilies (Lentivirinae and Spumavirinae). 
Historically, oncovirinae were divided into groups based on their morphology in negative
stained EM pictures: A-types are non-enveloped immature particles only seen inside cells
and believed to result from endogenous retrovirus-like genetic elements. B-types are
enveloped extracellular particles with a condensed, acentric core and prominent envelope
spikes (virus encoded glycocprotein). C-types are as B-types, but with a central core and
barely visible spikes, while D-types are usually slightly larger than the others (to 129nm).
Currently, most virus comparisons are based on sequence conservation (Table 1). 
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Table 1. Taxonomy: Group VI: RNA Reverse Transcribing Viruses
Family Genus Previous genus for type species Type Species genome Hosts
Retroviridae Alpharetrovirus Avian type C retrovirus Avian leukosis virus (ALV) simple Vertebrates
Betaretrovirus Mammalian type B retrovirus Mouse mammary tumour virus (MMTV) simple Vertebrates
Gammaretrovirus Mammalian type C retrovirus Murine leukaemia virus (MLV) simple Vertebrates
Deltaretrovirus BLV-HTLV retroviruses Bovine leukaemia virus (BLV) complex Vertebrates
Epsilonretrovirus Type D retrovirus group Wally dermal sarcoma virus simple Vertebrates
Lentivirus Human immunodeficiency virus-1 (HIV-1) complex Vertebrates
Spumaretrovirus Human spumavirus (HSRV) complex Vertebrates
Metaviridae Metavirus Saccharomyces cerevisiae Ty3 virus Fungi
Errantivirus Drosophila melanogaster gypsy virus Invertebrates
Pseudoviridae Pseudovirus Saccharomyces cerevisiae Ty1 virus Invertebrates
Hemivirus Drosophila melanogaster copia virus Invertebrates
Generated from Cann (2001) and the ICTV (International Committee of Taxonomy of Viruses) database
 http://www.ncbi.nlm.nih.gov/ICTVdb/canintro1.htm 
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Unless specified otherwise, the following section is based on Coffin et al. (1997) and Cann (2001). 
Retroviruses structure and genome
All retroviruses contain minimally three genes, gag, pol, and env, which encode the
structural proteins as well as the enzymes required for virus integration. There is a universal
nomenclature for retroviral proteins: 
Table 2: Retroviral proteins essential for replication (illustrated in Fig. 4A).
gene Name Protein Function:
gag MA Matrix a matrix protein that lines envelope
gag CA Capsid a capsid protein that protects the core
gag NC Nucleocapsid a capsid protein; protects genome and forms the core
pro PR Protease essential for gag protein cleavage during maturation
pol RT Reverse transcriptase reverse transcribes the RNA genome; 
has also RNAseH activity
pol IN Integrase needed for integration of the provirus 
env SU Surface glycoprotein outer envelope glycoprotein and major virus antigen
env TM Transmembrane protein inner component of the mature envelope glycoprotein
The outer envelope glycocprotein (SU) is responsible for receptor binding and is linked by
disulphide bonds to the transmembrane glycocprotein (TM) which holds the SU protein in
the envelope and is responsible for membrane fusion. Inside the envelope membrane is the
rather amorphous matrix (MA) protein that obscures the capsid (CA), which is believed to
be icoasahedral. Inside the capsid is the core including the RNA genome, nuclocapsid
(NC), Reverse transcriptase (RT) and, integrase (IN). 
All retrovirus genome consist of two molecules of RNA, which are s/s, (+) sense and have
5’cap and 3’ poly- (A) (equivalent to mRNA). These vary in size from ~8-11 kb. The two
RNA molecules are physically linked by hydrogen bonds. In addition, there is a specific
type of tRNA (usually trp, pro, or lys) presented in all particles (required for replication).
Gene order in all retrovirus is invariant: 5’-gag-pol-env-3’. The gag directs the synthesis of
internal virion proteins that form the matrix, the capsid, and the nucleoprotein structures.
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The mature product of the pol gene is a complex of polypeptides, which includes three
distinct enzymatic activities (reverse transcriptase, RNAse H, and integrase). The env codes
the surface and transmembrane components of the viral envelope protein (summerized in
Table 2). An additional, smaller, coding domain present in all retroviruses is pro, which
encodes the virion protease. Complex retroviruses have additional genes (illustrated in Fig.
1c and Fig. 5; and described below).
Viral life cycle
The steps involved in a generalized retrovirus life cycle are shown in Fig. 1b. The HIV-1
life cycle is shown in more detail in Fig. 4. To initiate the infection, the SU envelope
glycoprotein binds to a specific receptor on the surface of the host target cell. The
specificity of this interaction does much to determine the cell-tropism and pathogenesis of
different retroviruses, or different variants of the same virus. Murine retroviruses are sub-
divided on the basis of receptor-determined host species specificity: Ecotropic viruses
infect only mouse cells, xenotropic viruses infect only non-mouse cells (e.g., rat), and
amphotropic viruses infect both mouse and non-mouse cells (Battini et al., 1992). In
recent years, a number of different retrovirus receptor molecules have been identified
(reviewed in Sommerfelt, 1999). The cell-surface receptor for ecotropic murine leukaemia
viruses (MuLVs) has been shown to be a cationic amino acid transporter (Kim et al., 1991;
Wang et al., 1991; see Fig. 10). 
Penetration and uncoating are poorly understood, but it is clear that uncoating is only
partial, resulting in a core (nucleocapsid) particle within the cytoplasm. Reverse
transcription occurs inside the ordered structure of this core particle. The mechanism of
reverse transcription of retrovirus RNA genomes, in which two molecules of RNA are
converted into a single double-stranded DNA provirus, is illustrated in Fig. 2.
INTRODUCTION
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Figure 1. (a) Retroviral phylogenetic tree, (b) the life cycle of retroviruses, and (c) representative
genomic structures of simple (F-MuLV) and complex (HIV-1) retroviruses. See text for details. The
figure is from Power (2001).
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Figure 2. Reverse transcription of retrovirus RNA genomes. The figure is from Cann (2001). 
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The RNA genome of retroviruses is flanked by two short, redundant R sequences at both
termini. These are adjacent to unique sequences, U5 and U3, found at the 5’ and 3’ ends,
respectively. The provirus differ from the vRNA in being longer by one U3, R, U5
sequence. As a result there is a direct repeat of this sequence presented at each end of the
provirus genome, known as the long terminal repeat (LTR). Three forms of double-
stranded DNA are found in retrovirus-infected cells following reverse transcription: linear
DNA and two circular forms, which contain either one or two LTRs. The linear form
integrates into the host’s genome. Genomic integration is thought to be semirandom,
occurring preferentially at transcriptional active sites (Scherdin et al., 1990). Retroviral
infection of a cell is permanent, as proviruses are almost never lost from the chromosome. 
Once integrated into the host cell genome, the DNA provirus is dependent on the host-cell
transcription machinery for gene expression. Viral transcription is carried out by cellular
RNA polymerase II, which initiates in the upstream LTR at the U3-R border and terminates
in the downstream LTR at the R-U5 border (yielding RNA identical to genomic RNA). For
polymerase II promoters, sequences upstream from initiation start site control transcription
(Dynan & Tjian, 1985). Thus, the U3 region sequences of the LTR are particular important
for retroviral transcription. This region contains proximal and distal promoter elements, as
well as enhancer sequences (see Fig. 3). The sequences that govern viral transcription and
the repertoire of transcription factors used by a particular retrovirus reflect the unique
characteristics of its own replication mechanism (e.g., simple retroviruses that infect
lymphoid cells depend on the activity of lymphoid-specific transcription factors). Thus, the
ability of a retrovirus to propagate in a given cell type is mainly determined by the tissue
specificity of the enhancer sequence in the LTR and the viral envelope (see above). 
To compress maximal information into a small genome, retroviruses make use of splicing
and ribosomal frameshifting. Splicing is regulated by the cellular apparatus, which interacts
with cis-acting sequences present in the mRNA. The proteins encoded by gag, pol, and pro
genes are expressed from a full length genomic RNA (vRNA). In Murine leukaemia virus,
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the pro gene is separated from the gag gene by terminal suppression. The env protein is
expressed from a spliced mRNA. In more complex retrovirus (e.g., Lentivirus), several
mRNAs are produced, and especially the pattern of splicing in HIV is very complex
(reviewed in Tang et al., 1999). 
The final steps in the retrovirus life cycle are viral assembly and release from the cell. For
MuLVs and HIV, the assembly occur at the cell surface. Thickened patches begin to form
in the membrane (env proteins on outer surface, and gag proteins at the inside). The
genome is packaged as the particle buds out through the membrane. Maturation - the
phase of infection during which newly formed virus particles become infectious - involves
cleavage events catalyzed by the protease and condensation of the core.
Figure 3. Proviral LTR.
The organization of a prototypical Gammaretrovirus proviral LTR with its three regions U3, R, and
U5 is illustrated at the top. The arrowheads indicate two direct repeat (DR) sequences, understood
to be the viral enhancer (Golemis et al., 1990). The direct repeats (DRs), the promoter (CCAAT),
and the site of transcriptional initiation (TATA box) are all located in the U3 region. As in many
viral and cellular enhancer elements, each DR contains binding sites for multiple nuclear proteins. 
The Friend murine leukaemia virus variant FIS-2 LTR contains only one copy of a 66-bp repeat
(Dai et al., 1994). Bindings site for identified viral core element (core) and nuclear factors (Speck &
Baltimore, 1987; Manely et al., 1989) sequence are underlined: Friend virus factor a and b2 (FVa,
Fvb2), Leukaemia virus factor b (LVb) and Nuclear factor one (NF1). The gray box frames a
glucocorticoid response element (GRE) presented in the FIS-2 LTR U3 region (Dai et al., 1994). 
      --- --- ACATTGGGCCAAACAGGATATCTGTGGTGAGCAGTTTCGGCCCCGGCCCGGGGCCA AGAACAGAT  GG - ------
DR GRE
FVa
LVb
CORE NF1
FVb2
66 bp
U3      R      U5
Enhancer            CCAAT
                                       TATA
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Complex versus simple retroviruses
Retroviruses are broadly divided in two categories, simple and complex, distinguishable by
the organization of their genomes (Table 1 and Fig. 1c). Simple retroviruses usually carry
only the elementary information, whereas complex retroviruses code for additional
regulatory nonvirion proteins derived from multiply spliced messages. Murine leukeamia
viruses (MuLVs) are prototype simple retroviruses, while the Human immunodeficiency
virus (HIV-1) of the Lentivirus genus is among the most complex retroviruses known. The
lentiviruses are exogenous, nononcogenic (currently thought to induce cancer indirectly)
retroviruses, causing persistent infections. These viruses usually infect cells of the immune
system (T-cells, macrophages), and lentivirus infections are not cleared by the immune
system, leading to accumulated damage over a period of many years (lenti for slow). An
important characteristic not found in other retroviruses is their ability to infect nondividing
cells (Lewis & Emerman, 1994). HIV infection of non-dividing cellular targets like
macrophages requires successful passage of the viral preintegrated complex (PIC) across an
intact nuclear envelope (see Fig. 4). 
Compared with other retroviruses, lentiviruses have a larger genome (see Fig. 1c).
Lentiviruses most distinguished property is that they encode essential regulatory and
accessory genes that allow regulation of their own expression in the cell (reviewed in Tang
et al., 1999). Besides the common gag, pol, and env encoded proteins, HIV-1 has six
additional genes encoding the regulatory proteins Tat and Rev, together with the accessory
proteins Vif, Vpr, Vpu, and Nef (Fig. 5). 
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Figure 4. HIV life cycle.
(A) The mature virion is fully assembled after budding. 
(B) Completion of reverse transcription gives rise to the HIV preintegration complex (PIC). Unique
but redundant nuclear import signals resides within the HIV integrase, matrix, Vpr proteins, and the
“DNA flap” (corresponds to a triple-stranded intermediate created during reverse transcription).
These signals appear to facilitate PIC transport through the limiting nuclear pores. It should be
noted, that integration and infection are reduced in non-dividing host cells, were deoxynucleotide
concentrations are below Km value of retroviral RTs (Coffin et al., 1997).  
(C) The HIV life cycle. HIV fuses with the CD4 and cognate coreseptor, initiating fusion and
uncoating. The subsequent complex facilitates conversion of viral RNA into cDNA and sheds
several proteins while it traverses the cytoplasm along microtubule towards the nucleus. The PIC
somehow enters through the limiting nuclear pore complex to gain access to host chromosomal
DNA. After integration, genomic viral RNA is exported along with the immature viral particle
components, which assemble and bud together out of the cytoplasm through lipid rafts.
 Reviewed in Greene & Peterlin (2002). The figure is from Sherman & Greene (2002).
INTRODUCTION
11
Figure 5. Genome of the HIV provirus.
An overview of the organization of the ~9-kilobase genome of the HIV provirus and a summary of
the functions of its 9 gene encoding 15 proteins. The figure is from Greene & Peterlin (2002)
INTRODUCTION
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II: Retroviruses and pathogenesis
Retroviruses give rise to a broad spectrum of diseases, including neurological disorders,
malignant transformation, and immunodeficiencies. The AIDS epidemic associated with
HIV infections is currently the single greatest threat to public health worldwide (Piot et al.,
2001). It should be emphasized, though, that most retroviruses do not give rise to any
disease symptoms. Further, except from HIV and HTLV-1, the majority of disease-causing
retroviruses are found in non-humans (Coffin et al., 1997). Nevertheless, studies of
retrovirus induced diseases have made huge contributions to e.g., cancer research, with
subsequent revolutionary impact on fundamental concepts in modern biology (see Table 3).
Only a brief introduction to retrovirus induced malignant transformations and
immunosuppression, including HIV-1/AIDS, will be presented here. A glossary of
frequently used terms in medical virology & immunology is enclosed in the appendix
section.
Retrovirus induced oncogenesis.
It is now well accepted that evolution of cancer is a multistep process associated with the
activation of oncogenes and inactivation of tumour suppressor genes (reviewed in Yokoto,
2000). Studies of retroviral-induced oncogenesis in animal systems led to the initial
discovery of viral oncogenes (v-onc) and their cellular homologues (c-onc), and provided
critical insights into their role in the neoplastic process (Coffin et al., 1997; Jonkers &
Berns, 1996; Butel, 2000). The retroviruses which can transform cells fall into three groups:
(i) Transducing, acutely transforming viruses, which carry oncogenes (v-onc); (ii) cis-
activating, chronic transforming viruses, which do not have an oncogene present but
activate c-onc in cell genome by proviral insertion (see Table 4); and (iii) trans-activating
viruses, which activate cellular proteins by trans-activating virus protein (e.g., HTLV-1
encoded Tax). 
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Table 3: Selected major breakthroughs in the science of Retrovirology up to the
discovery of human immunodeficiency virus.
Major findings References
1908 Vilhelm Ellermann and Oluf Bang searched for an
infectious cause (bacterium) for leukaemia in chicken.
They succeeded in transferring the disease from one
chicken to another by cell-free tissue filtrates, and
thereby showed that virus caused the chicken leukosis.
Ellermann & Bang, (1908)
1911 Peyton Rous reported cell free transmission of sarcoma
in chicken and isolated the infectious agent, Rous
Sarcoma Virus (RSV). This discovery was followed by
many other examples of acutely transforming
retroviruses. Several of the retroviruses isolated became
important model systems, actively studied at the cellular
and molecular levels to this day.
Rous (1911)
Received the Nobel prize in 1966
1951 Gross observed vertical (germ line) transmission of
cancers
Gross (1951)
1957 The Friend murine leukaemia virus provided an animal
model system for the study of erythropoiesis and the
multistep nature of cancer. 
Friend  (1957)
1958 Focus assay for RSV introduced the “one cell, one virus
paradigm”
Temin & Rubin (1958)
1960’s Howard Temin knew that retrovirus genome were
composed of RNA and observed that replication was
inhibited by actinomycin D (that inhibits DNA
synthesis). This drug does not inhibit the replication of
other RNA viruses. Temin and Baltimore simultaneously
published the observations that retrovirus particles
contain an RNA-dependent DNA polymerase - reverse
transcriptase.
Temin & Mizutani (1970)
Baltimore (1970)
Received the Nobel prize in 1975.
1969 Huebner and Todaro proposed the viral oncogene
hypothesis (the transmission of viral and oncogen
information as genetic elements). Explained the vertical
transmission of cancers, first observed by Gross (1951)
Huebner & Todaro (1969)
1981 Human T-cell leukaemia virus discovered, the first
pathogenic human retroviruses
Gallo et al., (1981)
1983 Human immunodeficiency virus (HIV) discovered - the
causative agent of AIDS.
Barre-Sinoussi et al., (1983)
Gallo et al., (1984)
Adapted from Cann (2001) and Coffin et al. (1997).
INTRODUCTION
14
Retroviruses that lack v-onc genes are usually replication competent, do not transform cells
in culture, and induce tumours with long latent period in vivo. Most retroviruses that lack
oncogenes cause hematopoietic malignancies, although a few of these viruses induce
carcinomas. In the next section, some murine retroviruses that lack v-onc are described as
examples. 
Table 4: Cellular oncogenes activated by insertion of retroviruses lacking oncogenes.
General class Oncogene Virus Protein product
Non-receptor protein TK LcK Mo-MuLV Tyrosine kinase
c-fms F-MuLV CSF receptor
Serine/threonine TK Piml Mo-MuLV Serine/threonine kinase
Growth factor Fgf3/Int2
Wnt1/Int1
Wnt3/Int4
MMTV
MMTV
MMTV
Fibroblast growth factor
Secreted glycocprotein
Secreted glycoprotein
G-protein c-Ki-ras F-MuLV GDP/GTP binding
Transcription factor Ets1
c-myb
c-myc
Mo-MuLV
Mo-MuLV
Mo-MuLV
Transcription factor
Transcription factor
Transcription factor
Cyclin Fis1/Cyclin D1
Vin1/ Cyclin D2
F-MuLV
Mo-MuLV
G1 cyclin
G1 cyclin
CSF: Colony stimulating factor; TK: tyrosine kinase; Mo-MuLV: Moloney murine leukaemia virus; F-
MuLV: Friend murine leukaemia virus. Adapted from Coffin et al. (1997) and Butel (2000). The list is
representative, not exhaustive. In humans, no mechanism such as oncogene activation by proviral insertion
has been reported, but genes identified in animal models are also found mutated or overexpressed in human
tumours.
Mouse mammary tumour virus (MMTV) of the genus betarerovirus can induce
mammary carcinomas in mice late in life by activation of proto-oncogenes after integration
in their vicinity. Common integration site for MMTV is close to int genes that codes for
extracellular growth factors (reviewed in Jonkers & Berns, 1996). Exogenous MMTV is
spread via the milk of infected females and is acquired by suckling pups. On rare occasions,
an exogenous MMTV provirus is inserted into germ or early embryonic cells, thereby
becoming a stable inherited endogenous provirus. MMTV, like most retroviruses, is
dependent on cell division to complete its replication cycle. Interesting, it requires a
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functional immune system to achieve efficient infection of the mammary gland, and
MMTV has developed at least two strategies to exploit the immune response. During
primary infection, MMTV is transmitted in the milk from the mother to the newborn and is
taken up in the intestine, where it infects local lymphocytes (reviewed in Ross, 2000).
Infected B-cells express a 3'-LTR-encoded superantigen (Sag) on their surfaces that
interacts with the V chains of the T-cell receptor on specific T-cell subsets (reviewed in
Acha-Orbea & MacDonald, 1995). These immune reaction results in a preferential clonal
expansion of infected B-cells, thus facilitating the persistence of the virus in the organism
until the target mammary tissue develops. Further, MMTV also activates B-cells via
interaction with toll-like receptor 4 (TLR4) at an early stage of infection, and this activation
is independent of viral gene expression (Rassa et al., 2002). Thus, the use of a receptor
involved in innate immunity (Takeda & Akira, 2001) represent a second way this virus has
evolved to take advantage of the immune system. 
Since MMTV does not encode an oncogene and cause tumours by integrating near cellular
oncogenes and activating or altering their transcription, the more cells that become infected,
the greater the likelihood that an oncogenic integration will occur. The mammary gland
specificity of the oncogenic property of MMTV depends on the high viral replication rate
and consequent high reinfection rate in the mammary epithelial cells, which are stimulated
by pregnancy-related hormones (Coffin et al., 1997; Ross, 2000). 
The Friend murine leukaemia virus complex (FV) was first characterized by Charlotte
Friend (Friend, 1957) and has become one of the best animal tumour models to study the
multistep nature of cancer (Ben-David & Bernstein, 1991; Ney & D’Andrea, 2000). The
FV complex consists of two components: the spleen focus-forming virus (SFFV), a
replication defective virus which is responsible for an acute pathogenicity, and Friend
murine leukaemia virus (F-MuLV), which acts as a helper for the replication of the
defective SFFV. Although SFFV lacks a classical oncogene and consists entirely of
retroviral-specific sequences, it encodes a unique envelope glycoprotein (gp55), which
INTRODUCTION
16
interacts specifically with the EpoR at the cell surface, resulting in activation of the
receptor and subsequent activation of erythroid signal transduction pathways (Li et al.,
1990). However, the interaction of the SFFV envelope glycoprotein (gp55) with the EpoR
is not sufficient to transform cells. The emergence of clonal tumorogenic cells during later
stages of the disease is dependent upon proviral insertional mutagenesis (Jonkers & Berns,
1996). Critical elements of the disease involve the interaction of host gene products
Sfpi/PU.1 and SF-Stk, as well as EpoR. SFFV proviral integration at Sfpi-1 (spleen focus
forming virus proviral integration site 1) leads to rearrangement and transcriptional
activation of the PU.1 gene, which encodes an Ets-related transcriptional factor that is
normally expressed in machrophages and B-cells (reviwed in Ruscetti et al., 1999). The Stk
is a member of a large family of surface tyrosine kinase receptor, while EpoR is a member
of a large family of cytokine receptors. The binding of gp55 to EpoR stimulates
uncontrolled erythroblast proliferation and increases the migration of erythroid precursors
from the bone marrow to the spleen. Such expansion of mitotically activated target cells is
thought to be essential for FV-induced malignant transformation because of the increased
probability of proviral integration. Thus, when adult mice of susceptible strains (described
below) are infected with FV, their spleens rapidly enlarge because of virus induced
polyclonal proliferation of erythroid precursors cells. Subsequent proviral integration at the
Sfpi-1 (ets) oncogene locus combined with inactivation or mutation of the p53 tumour
suppressor gene produces fully malignant erythroleukaemia. This process results in gross
splenomegaly at 8-9 days post infection and transplantable erythroleukaemia cells as early
as 15-20 days post infection (for review on Friend erytroleukaemia, see Ruscetti, 1999; Ney
& D’ Andrea, 2000). 
Two different Friend virus strains have been isolated, FVa and FVp, which, due to different
SFFV virus components induce different subsets of early erythroid cells to expand
polyclonally: SFFVa (anaemia) causes expansion of non-haemoglobin synthesizing cells
which are dependent on erythropoietin, whereas SFFVp (polycythemia) induces
erythropoietin-independent cells actively synthesizing haemoglobin. The helper virus F-
INTRODUCTION
17
MuLV is capable of inducing erythroleukaemia independently of SFFV when injected into
newborn mice of susceptible strains. The F-MuLV-induced erythroleukaemia has a disease
pattern very similar to that induced by SFFVa, and also results in early rapid expansion of
epo-dependent erythroid precursors, followed by clonal outgrowth of malignant
erythroleukaemia cells  (reviewed in van Lohuizen & Berns; 1990). 
Murine leukaemia viruses (MuLVs) of the genus gammaretrovirus can induce a large
spectrum of pathologic responses in mice, with a predominance of hematopoietic tumours.
Transformation is usually achieved by retroviral integration at the vicinity of a cellular
proto-oncogene. Several insertion sites have been identified, and among them are many loci
that contain genes that become deregulated due to proviral integration (see Table 4).
Although MuLVs can infect many tissues and cell types, each virus will induce a specific
type of tumour (e.g., T or B lymphomas, myeloid leukaemia, or erythroleukaemia). Several
studies have shown that the strength or tissue specificity of the LTR enhancers may affect
the pathogenic behaviour of nonacute retroviruses (selected references: Evans & Morrey,
1987; Ishimoto et al., 1987; Thiesen et al., 1988; reviewed in Athas et al., 1994, and Fan,
1990). Fan (1990) suggested that a retrovirus with a strong enhancer might more efficiently
activate a proto-oncogene and more rapidly induce tumours than one with a weaker
enhancer. Further, the tissue-specific replication of different MuLVs is conferred by their
LTRs (Evans & Morrey, 1987). 
Experiments with different MuLVs such as Mo-MuLV and F-MuLV, which induces T-
cell lymphoma and erythroleukaemia in neonatal mice, respectively, have shown that both
the type of leukaemia induced and the incubation period for leukaemia induction are largely
determined by the U3 region of the respective LTR: (i) The distinct disease specificity of
Mo-MuLV and F-MuLV may be entirely switched by exchanging a segment of the U3
region of the LTR (Chatis et al., 1984; Golemis et al., 1989). (ii) A two-nucleotide
mutation in the enhancer core of Mo-MuLV (TGTGGTAA to TGCCGTAA) altered the
disease specificity from 100% T-cell lymphoma to 65% erythroleukaemia (Speck et al.,
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1990). (iii) A deletion in the tandem repeat of the F-MuLV LTR (see Fig. 3) attenuated the
leukemogenesis of F-MuLV (Li et al., 1987; Sitbon et al., 1991). Overall, these studies
showed that subtle alterations in the highly conserved structure of the mouse type C
retrovirus U3 region (Golemis et al., 1990) could be sufficient to confer distinct biological
properties to the virus.
Retrovirus induced immunosuppression
Most, if not all, pathogenic retroviruses induce a generalized immunosuppression in the
infected host. Human and simian immunodeficiency viruses (HIV and SIV) induce a
pronounced immunosuppression, ultimately leading to AIDS (described below). Marked
impairment of the immune system has also been described in cats infected with the feline
immunodeficiency virus (FIV) (Pedersen et al., 1989), and in mice infected with several
murine leukaemia viruses (MuLVs) as well as the Friend leukamia virus complex
(Bendinelli et al., 1985; Friedman et al., 1983; Soldaini et al., 1989). Furthermore, murine
AIDS (MAIDS), characterized by a lymphoproliferative disease and a profound anergy
which involves mostly CD4+ cells, develops following infection with the MAIDS (LP-BM5
MuLV) virus complex (reviwed in Mosier, 1996). 
The prototype immunosuppressive virus, HIV-1, causes a spectrum of clinical problems
beginning at the time of seroconversion, and terminating with AIDS (acquired
immunodeficiency syndrome) and death. During primary infection with HIV, high levels of
viremia develop within days to weeks (Daar et al., 1991). Viremia reaches a peak and the
CD4+ cell count temporary decreases. Subsequently, as the host mounts a vigorous immune
response that partially controls viral replication, a (hypothesized) viral set point is reach,
reflecting a tenuous balance between production and destruction of virions. The host enters
a largely asymptomatic phase during which viremia persists, and billions of virions and
CD4+ cells are produced and destroyed daily. Eventually, progression to disease occurs,
characterized by steadily increasing viremia, decreasing CD4+ cell counts, and, finally,
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profound immunosuppression, clinically recognized as AIDS. Various complications
characterize AIDS, including wasting, neurological impairment, opportunistic infections
and malignancies (reviewed in Levy, 1998; Mindel & Tenant-Flowers, 2001). 
Diverse clinical courses can occur after HIV infection (reviewed in Haynes et al., 1996;
Hogan & Hammer, 2001, a and b): (i) Rapid progressors are HIV-infected subjects which
progress to AIDS within the first 2 to 3 years of HIV infection. (ii) Long-term
nonprogressors are clinical asymptomatic after 7 to 10 years and have stable CD4+ T cell
level. Some of these HIV-infected persons will be AIDS free for decades. (iii) Typical
progressors are projected to develop AIDS within median time of approximately 10 years
from initial infection (Fig. 6). 
 
Figure. 6. A schematic diagram of events occurring after HIV infection. Patterns of CD4+ T-cell
decline and virus load increase vary greatly from one patient to another, as do the actual values of
viral RNA load. Further, the course of HIV infection varies widely among individuals (se text). The
figure is generated from Coffin et al. (1997), and is representative for a typical progressor.
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Immunosuppression by retroviruses is a complex phenomenon involving many different
cell types of the immune system, and several mechanisms for immunosuppression by
retroviruses have been suggested, including (i) killing of infected target lymphocyte; and
(ii) modulation of cytokine production and/or induction of a TH1/TH2 imbalance (see Fig.
7) (reviewed in Bendinelli et al., 1985; Cann, 2001; Coffin et al., 1997; Denner, 1998).
Retroviruses that cause immune deficiency often do so by infecting activated lymphocytes,
including those involved in the immune response to the retroviruses. Thus, the most likely
explanation is that immunological dysfunction are produced directly by viral replication in
the affected cells. For example, HIV-1 preferentially infects HIV-specific CD4+ T-cells
(Douk et al., 2002). The HIV infection of CD4+ T-cells leads to the loss of critical
regulatory cells in the immune system, with CD4+ T-cell number and viral load being the
most sensitive predictors of disease progression (Fig. 6). Recent observations support a
close linkage between immune activation and CD4+ cell depletion in HIV infection and
only an indirect relationship of these parameters to the virus rate of replication (Sousa et
al., 2002; reviewed in Grossman et al., 2002). 
One of the most thoroughly studied viral candidates for the immunosuppressive actions of
retroviruses is the transmembrane envelope protein (TM). A hydrophilic 26-amino acid
sequence of the otherwise hydrophobic TM protein, p15E, of feline and murine leukaemia
virus is conserved among TM-proteins of murine, feline, simian, human-T-cell leukaemia
retroviruses, and partly HIV (reviewed in Denner, 1998). Cianocilo et al., (1985)
synthesized a 17 amino acid peptide, CKS-17, representing the conserved domain within
this region. Several studies have shown that this prototypic immunosuppressive domain
elevate intracellular cAMP (Haraguchi et al., 1995a), activates MAP-kinases (Takahashi et
al., 2001), and suppress numerous immune functions (Table 5). It has been reported that
activation of the MAP kinase pathway plays a role in enhancing HIV infection and
replication (Yang & Gabuzda, 1999), as well as suppressing TH1-related cytokine
production (Feng et al., 1999). Haraguchi et al., (1995b) have shown that CKS-17 can act
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as an immunomodulatory epitope causing imbalance of the TH1- and TH2- related cytokine
production and suppression of cell mediated immunity (discussed below; illustrated in Fig.
7). CKS-17 may excert its immunosuppressive activity via activation of the cAMP/protein
kinase A (PKA) patway and inhibition of the protein kinase C (PKC) pathway (reviwed in
Haraguchi et al., 1995c). Recently, Andahl et al., (2002) showed that cAMP through
activation of PKA type 1 is a universal inhibitor of T-cell function. Further, hyperactivation
in the cAMP/PKA system has been implicated in the T-cell dysfunctions associated with
HIV (Aandahl et al., 1998; reviwed in Torgersen et al., 2002) and MAIDS-associated T-
and B-cell anergy (Rahmouni et al., 2001).
Table 5: Immunosuppressive activity of the retroviral TM protein 
In vitro
 mitogen induced proliferation of T and B
lymphocytes
 mixed lymphocyte reaction
 IL-2-induced proliferation of T cell lines
 respiratory burs of monocytes
 chemotaxis of monocytes
 natural killer cell (NK-cells)
 erythroid colony-forming units (CFU)
In vivo
 machrophage accumulation
 antibody response to cell surface antigens
 enhancement of tumour progression
From Denner (1998)
However, it is not known how much of the pathology (e.g., AIDS) is related to individual
genetic traits of the immune system and how much is caused by the virus. Thus, although
immunosuppression by retroviruses was first described over 40 years ago (Old, 1959), and
although enormous efforts have been undertaken to study its mechanisms because of the
AIDS epidemic, the answer to how it works is still enigmatic. 
The next paragraph gives a brief description of animal models currently used to study the
basic mechanisms whereby a retrovirus persists and immunosuppress the host.
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III: Animal models for retrovirus-induced immunosuppression 
For the first decade of the AIDS epidemic, researcher conducted experiments in
chimpanzees held in primate colonies (Fultz et al., 1989). Because these animals are
endangered and expensive, researchers have more recently used rhesus monkeys, originally
from India. These monkeys develop an AIDS-like disease when infected with either simian
immunodeficiency virus, SIV, or a laboratory-made SIV/HIV hybrid called SHIV
(reviewed in Joag, 2000). Other currently available animal models of AIDS includes feline
immunodeficiency virus infection (FIV) of cats (Pedersen et al., 1989), HIV-1 infections of
rabbit (Kulaga et al., 1989), and SCID mice reconstituted with human tissues or cells
(reviwed in Bonyhadi & Kaneshima, 1997; Mosier et al., 1996). Further, mice infected
with simple retroviruses such as LP-BM5 MuLV complex (Coffin et al., 1997; Mosier,
1996) or FV (Bendinelli et al., 1985; Hasenkrug & Dittmer, 2000) offers model systems for
studies of more general aspects regarding retrovirus induced immune dysfunctions. The
next few paragraphs briefly describe the SIV and FIV viruses as examples of complex
retrovirus models. The Friend virus model is described as an example of
immunosuppression induced by simple retroviruses in mice. These models are also used in
vaccine research.
Complex retrovirus models
Simian immunodeficiency viruses (SIVs) are a group of HIV-related, but distinct,
lentiviruses isolated from several different African primates including chimpanzees
(SIVcpz), sooty mangabeys (SIVsm), mandarills (SIVmnd), and African green monkeys
(SIVagm) (Holterman et al., 1999 and references therein). The primate lentiviruses have
little or no pathogenicity in their natural hosts, and disease appears to result only after
transmission to another species. It has been confirmed that SIVcpz is the progenitor of HIV-
1 (Gao et al., 1999). Some SIV strains, like pathogenic isolates of SIVmac251, induce AIDS
in macaques. Highly pathogenic SIV isolates results in loss of CD4+ T-cells within six
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months and death by one year. The availability of molecular clones of SIVs that vary in
cellular tropism and virulence makes this experimental model particular useful (reviewed in
Joag, 2000; Johnston, 2000). Further, infection of macaque monkeys with simian
immunodeficiency virus is still the best model for HIV vaccine research (reviewed in
Warren, 2002). 
Feline immunodeficiency virus (FIV)
FIV, a lentivirus of cats that causes a disease similar to human AIDS (Pedersen et al.,
1989), has been developed as a naturally occurring small animal model for HIV infection
and disease (Willett et al., 1997). Cats infected with FIV progress from acute to
asymptomatic infection, followed by increasing immune dysfunctions and finally an AIDS
like disease. As with HIV infection, the course of disease development is prolonged, taking
several years in most cats to reach the AIDS stage. During that time, the CD4+ cell subset
declines, cytokine profile changes, and macrophage functions are disrupted (Ackley et al.,
1990; Barlough et al., 1991; Lawrence et al., 1995; Willett et al., 1997). 
Simple retrovirus models
The Friend murine leukaemia virus complex (FV) is one of the classical murine models
used to study immunosuppression associated with retrovirus infection (Bendinelli et al.,
1985; Soldaini et al., 1989). FV replicate in numerous cell types including macrophages, B-
lymphocytes, and to a lesser extent, T lymphocytes (Soldaini et al., 1989). Considerable
immunosuppression, involving both humoral and cell-mediated responses, is strongly
affected by FV infection. For example, the specific response of B-cells to certain T-cell
dependent antigens such as sheep red blood cells (SRBC) is depressed severely early after
infection in immunecompetent susceptible adult mice (Bendinelli et al., 1985; Ceglowski &
Fridman, 1970). Responses to T-independent antigen have also been reported (Morrison et
al., 1986). The ability of T-cells to mediate cytolysis of allogenic target cells is reduced
(Mortensen et al., 1974), and the generation of cytotoxic T-cells is impaired (Garaci et al.,
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1981). Modulation of cytokine production, including increased IL-1 production and
reduced IL-2 production are observed (Soldaini et al., 1989). Further, decreased NK-cell
activity (Lu et al., 1992), as well as impaired antigen presentation by machrophages (Jones
et al., 1992) have been associated with FV-infection. The symptoms of a general immune
suppression which are immediately associated with FV infection in some mouse strains
have been considered very similar to those observed in AIDS patients (Morrison et al.,
1986; Soldaini et al, 1989). Many of the dysfunctions induced by FV are also observed in
F-MuLV infected mice. However, the immunosuppressive effects of F-MuLV are less
severe.
Friend immunosuppressive variant, FIS-2. 
When HIV emerged on the scene, the FV-induced immunosuppression again gained
attention and was suggested as a murine model of AIDS (Soldaini et al., 1989). However,
the immunosuppressive effects in FV infected adult mice are soon overwhelmed by the
massive infiltration of leukaemia cells (see above). The initial goal of “The FIS-2 project”
was to isolate an immunosuppressive but low oncogenic variant of FV, and to develop a
more available murine model to study retrovirus induced dysfunctions. To obtain such a
variant, lysates of T-helper cells from FV infected NMRI mice were passed to recipient
uninfected mice. A group of these mice developed a condition distinct from the disease
induced by FV, and a viral stock prepared from these mice induced a profound suppression
of the primary antibody response without acute transformation (Faxvaag et al., 1993a). This
stock (initially named Fd-MIV for Friend derived murine immunodeficiency virus) was
used to investigate retrovirus induced derangement of cytokine homeostasis (Faxvaag et al.,
1993b; Faxvaag et al., 1995), polyclonal activation of B-lymphocytes, and induction of
autoimmunity (Faxvaag et al., 1993c). 
Analysis of viral DNA and RNA from infected NIH 3T3 cells showed that the virus stock
contained a mixture of at least two viral components, a replication-competent F-MuLV-
related virus and a replication-defective mink cell focus-forming virus (MCF) related virus.
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Since the MCF related genome was not detected in infected, immunocompromised mice, it
was assumed that the F-MuLV related virus component was responsible for the disease
(Faxvaag et al., 1993a). In order to prove this, two biological clones designated Friend
immunosuppressive variant-1 and -2 (FIS-1 and FIS-2), were obtained from NIH 3T3 cell
inoculated with spleen extract from mice in early and advance stages of disease,
respectively (Dai et al., 1994). Southern blot analysis showed that the defective viral
component was eliminated during the procedure of end-point dilution. Only mice
inoculated with FIS-2 became immunosuppressed. FIS-2 was further molecularly cloned
and characterized. Restriction mapping and nucleotide sequence analysis of FIS-2 showed a
high degree (about 95%) of homology between FIS-2 and the prototype F-MuLV clone (cl.)
57 (Troxler et al., 1980), suggesting that FIS-2 was a variant of F-MuLV. However, there
were some striking differences between FIS-2 and F-MuLV cl. 57 (Dai et al., 1994): 
Differences in the LTRs: 
 The second copy of the direct repeat (74 bp) in the F-MuLV LTR had been completely
deleted from the FIS-2 LTR. 
 The sequence of the enhancer core element of the F-MuLV, TGTGGTAA, was changed
to TGTGGTGA in FIS-2. 
 A single-nucleotide transition of G to A occurred in the binding site of factor FVa, and
because of the deletion of the second copy of the direct repeat, the binding site for
nuclear factor FVb1 was missing in the FIS-2 LTR.
 A binding site for the glucocorticoid receptor GR, a glucocorticoid response element
(GRE), AGAACAGATGG, had been generated in the FIS-2 LTR.
 Analysis of the nucleotide sequences of the LTRs of FIS-2 and SFFVp indicated that
the FIS-2 was generated by recombination between SFFVp and F-MuLV.
Differences in gag - encoded proteins: 
A total of 38 point mutation occurred scattered over the FIS-2 gag gene, and 24 mutations
led to amino acid changes in the gag product. Two single point mutations led to the
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appearance of two extra potential N glycosylation sites in the FIS-2 gag-encoded
glycoprotein.
Differences in Env – encoded proteins: 
Among the 23 amino acid mismatches found, 22 were distributed over the SU region. 
Most newborn mice infected with the FIS-2 clone developed erythroleukaemia, but with an
increased latency period compared with that of F-MuLV cl. 57. In contras, FIS-2 was
shown to induce suppression of antibody response against sheep erythrocytes (SRBC) in
adult NMRI mice more efficiently than the prototype F-MuLV cl. 57. Together these initial
studies (Faxvaag et al, 1993, a, b, and c; Faxvaag et al., 1995; Dai et al., 1994) suggested
that FIS-2 could represent an interesting murine model to study retrovirus-induced
immunosuppression on the basis of its combined property of low leukaemogenicity and
relatively strong immunosuppressive activity in adult mice. 
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IV: Virus-Host interactions
The overall course of a retrovirus infection is determined by a dynamic interaction between
the virus and its host organism. As described above, small differences in viral gene
sequences (e.g., in the LTRs) can have a dramatic effect on biological properties. Divergent
patterns of disease progression following infection from a common source virus are thought
to reflect different host responses. Some viral and host factors that may influence the
susceptibility and/or outcome of a retrovirus infection are summarized in Table 8.
Virus Factors
As described above, the events occurring after HIV infection is divided into several phases.
The quantity of virus in the blood is one of the major parameters characterizing the
primary acute infection, the prolonged asymptomatic phase, and the final AIDS phase
(Daar et al., 1991; D'Souza & Mathieson. 1996; Lyles et al., 1999). A correlation between a
high viremia level at the time of seroconversion (see Fig 6.) and early disease manifestation
has been documented (Ho, 1996; Mellors et al., 1996). Therefore, identification of the
factors affecting this viremia level has been an important objective in studies of
experimental SIV (Watson et al., 1997) and FIV (Diehl et al., 1995) infections. Some
studies in SIV infected monkeys demonstrated that peak viremia level correlated with the
level at which viremia stabilized after seroconversion (Lifson et al., 1997; Marx et al.,
1996). Other factors such as route of virus administration (Baba et al., 1996; Bosch et al.,
1997; Sodora et al., 1998; Triverdi et al., 1996) and early virus replication (Staprans et
al., 1999; ten Haaft et al., 1998) has also been studied.
It has been hypothesised that AIDS-causing lentiviruses can become more virulent upon in
vivo evolution and acquire the capacity to accelerate the progress to AIDS (Hirch, 1999;
Kimata et al., 1999). Holterman et al. (1999) did indeed show that selective transmission of
SIV from late-stage cases of AIDS in rhesus monkeys resulted in a SIV strain that was
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capable of inducing a highly accelerated AIDS-like syndrome with extremely high virus
load and rapid loss of CD4+ T-cells within weeks of infection. The animals progressed to
AIDS before an effective immune response could be mounted. 
In mice infected with the Friend virus complex, the severity of virus induced
immunosuppression is directly correlated with the virus dose inoculated (Bendinelli et al.,
1985; Ceglowski & Friedman, 1970). The incubation period of CasBrE (MuLV like virus)
induced spongiform neurodegenerative disease in mice can be dramatically shortened (from
150 days to 15 days) by concentrating the virus inoculum 1000-fold (Brooks et al., 1979;
Brooks et al., 1980). Similar effects of the virus dose have also been shown by others
(Czub et al., 1992).
Host factors
With the identification of HIV as the cause of AIDS, it seemed that a vaccine would follow
closely behind. However, despite a large concerted effort, the problem has proven more
difficult than anticipated, and researchers are still struggling to design a protective AIDS
vaccine. A remaining problem is a lack of basic knowledge about the immunological
requirements for protection against retroviruses (reviewed in Gandhi & Walker, 2002;
Johnson & Desrosiers, 2002; McMichael & Rowland-Jones, 2001; Nabel, 2001). 
A virus infection can activate both humoral and cellular arms of the immune system (Fig.
7). Innate immunity, such as phagocytes, natural killer (NK) cells, and complement, acts
rapidly and has an important role in the initial control of acute viral infections. Further,
cells of the innate immune system, such as dendritic cells are necessary to activate acquired
immunity. Acquired immunity consist of humoral (B-lymphocyte mediated) and cellular
(T-lymphocyte-mediated) responses. In addition, memory lymphocytes protect against re-
exposure to the viral pathogen. Antibodies prevent infection of cells, by opsonisation or
complement mediated lysis of the virus, and by antibody dependent cell-mediated
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cytotoxicity. The cellular immune responses to virus consist of both CD8+ cytotoxic T
lymphocyes (CTLs) and CD4+ T helper cells. Both CTL and T-helper cell recognize short
peptide fragments of viral proteins that bind to MHC molecules. Recognition of viral
peptide in conjunction with class I MHC on the surface of an infected cell by a CD8+
cytotoxic T lymphocyte leads to lysis of the infected cell. A CD4+ T-helper cell recognizes
viral peptide in conjugation with class II MHC on the surface of an antigen-presenting cell.
The T-helper cell is then activated to secrete lymphokines that coordinate CD8+ T-cell and
B-cell responses. 
Figure 7: Regulation of cell-mediated and humoral immune responses. 
Regulation of the immune system depends on a complex network of cells. CD4+ T helper (TH) cells
have a central role in this process. Immunological theory suggests that there are two types of these:
TH1 cells, which promote the cell-mediated response, and TH2 cells, which promote the humoral
response. Protection against retrovirus infections which requires both cell-mediated and humoral
effector mechanisms may be favoured by the development of a TH1 rather than TH2 CD4+ T-cell
response. The figure is from Cann, 2001.
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In most virus infections where the immune response has been studied, it is clear that both
humoral and cellular arms of the immune system are required for an optimum protective
response. Nevertheless, many retroviruses replicates well in otherwise healthy individuals,
despite strong, virus-specific immune responses (reviewed in Gandhi & Walker, 2002;
Jonson & Desrosiers, 2002). However, it is well known that there is genetic variation
among different individual hosts in their susceptibility to simple retroviruses like FV
(Chesebro et al., 1990; Hasenkrug & Chesebro, 1997; Ney & D’ Andrea, 2000), and
complex retroviruses like HIV-1 (Carrington et al., 1999; Paxton et al., 1996).
Host factors in FV infection.
As shown in Table 6, FV-induced diseases are genetically controlled by multiple non-H-2
linked virus susceptibility/resistance genes (Fv-1, Fv-2, Fv-3, Fv-4, Fv-5) as well as H-2
linked and non-linked immune response genes (Rfv-1, Rfv-2, Rfv-3). 
Table. 6. Host genes that affect susceptibility to Friend virus-induced disease
Gene Function
I Interference with
retroviral infection
Fv4
Fv1
Blocks retroviral cell surface receptors
Interferes with retroviral life cycle
II Altered immune
response
Rfv1, Rfv2
Rfv3
Susceptibility to immunosuppression
Non-H-2-linked determinant of immune responses
III Regulators of erythroid
cell proliferation
Fv5
Kit, Mgf
Fv2
Determines anemia versus polycythemia
Required for normal erythropoiesis
Determines proliferative response to gp55
Generated from Ney and D’Andrea (2000).
Adult mice with appropriate susceptibility allels at the nonimmunological loci (e.g., Fv-2s/s
or Fv-2r/s) are infectable by FV and develop severe splenomegaly (described above). Their
subsequent survival is dependent on specific major histocampatibility complex (MHC)
class I and II allels, and a non-MHC gene Rfv-3, which controls virus-specific antibody
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responses. Mice having high recovery MHC and Rfv-3 genotypes, such as H-2b/b and Rfv-
3r/s, respectively, spontaneously recover to near normal spleen size within weeks and
generally live out a normal life span. This phenomenon provides a system for the study of
host and virus factors that are involved in the control and eventually elimination of
retrovirus infection (selected references: Dittmer et al., 1999, 2001, and 2002; Hasenkrug &
Chesebro, 1997; Hasenkrug & Dittmer, 2000; Hasenkrugh et al., 1998; Hasenkrug 1999;
Stromnes et al., 2002).
Host factors in HIV-1 infection. 
As described above, the course of HIV infection varies widely among individuals.
Immunologic and genetic studies of long-term nonprogressors and exposed, yet uninfected
persons, have elucidated the complex interplay of host and virus factors that may determine
the course of HIV infection, or even the risk for initial HIV acquisition (reviewed in Hogan
& Hammer, 2001, a and b). Some host factors in HIV infection are summarized in Table 7. 
The effects of sex and steroid hormones. 
In addition to inter-individual host differences, gender related differences in susceptibility
to virus-infection and disease outcome has been reported, but not intensively studied (for
review and reports see, Weizemann & Pardue, 2001; Whitacre et al., 1999). Sex-related
differences in susceptibility to experimental virus infections have been reported for viruses
like the encephalomyocarditis virus (Curiel et al., 1993), the coxaxkievirus B3 (Huber et
al., 1999), the herpes simplex virus type 1 (Han et al., 2001), the vesicular stomatitis virus
(Barna et al., 1996), the Theiler’s murine encephalomyelitis virus (Hill et al., 1998), and
murine retroviruses (Gillespie & Rowson, 1968). Further, sex differences in HIV infected
humans have been observed (reviewed in Gandhi et al., 2002; and discussed below).
It is well known that there are sex differences in regard to immune functions, with females
having generally higher immunoglobuline levels and mounting stronger immune responses
following immunisation or infection than males (reviewed in Morell, 1995; Pelfrey, 2001; 
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Table 7: Host factors in HIV infection.
Host factors Effect on HIV transmission and disease progression
Cell mediated immunity
 Cytotoxic T-cells
 T-helper cell response
Eliminates virions and virus infected cells; plays prominent role in
initial control of viremia, slowing of disease progression, and perhaps
prevention of infection.
Preservation of this response may be vital to preservation of cytotoxic
T-cell response, and its importance provides theoretic rationale for
early treatment.
 
Humoral immunity Role in prevention and control of disease is unclear.
Local factors
 STDs 
 Mucosal immunity
 Dendritic cells 
May upregulate HIV replication
Role in prevention of transmission and disease progression is unclear.
Facilitate HIV infection of T-cells by capturing and transporting HIV
to lymph nodes and activating T-cells. 1)
Chemokine receptors
 CCR5-∆32
 CCR2-V641
 CCR5 promotor 
Homozygosity for this deletion is associated with decreased
susceptibility to R5 virus infection; heterozygosity is associated with
delayed progression to disease.
Heterozygosity is associated with delayed progression to disease.
Several genetic polymorphisms that may affect transsmission or
disease progression have been identified.
Chemokines
 SDF-1 3’
 Cytokines
Homozygosity may be associated with delayed progression to disease
Complex interplay of stimulatory and inhibitory cytokines affects
HIV replication.
Other genetic factors
 HLA alleles Certain alleles are associated with differing susceptibility to infection
and rates of disease progression.
The table is generated from Hogan & Hammer, (2001, a and b): Host determinants in HIV infection and
disease, part I and part II. SDF= stroma cell-derived factor; STD = sexually transmitted disease
1) Many cell types, including erythrocytes (Hess et al., 2002), can bind HIV directly through cell-surface
receptors or via attachment of HIV immune complexes to cellular receptors. Infectious virus can then be
transferred to various target cell (Levy, 2002).
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Verthelyi, 2001; Whitacre et al., 1999). Estrogens and progestins appear to have complex
roles in regulating the balance between pro- and anti-inflammatory signals, primarily via
the production of immunoregulatory cytokines (Correale et al., 1998; Piccinni et al., 2000).
Progesterone, which is generally considered anti-inflammatory, often opposes estrogen
effects (Hunt et al., 1997). Further, estrogen have been demonstrated to induce a TH1 type
immune response, while progesterone, as well as glucocorticoids, induce a TH2 shift in
vitro (Miyaura & Iwata, 2002; Whitacre et al., 1999).
A few studies have reported that sex-steroid hormones may influence retrovirus infections.
For example, in ovulating women the HIV-1 load has been shown to fall during the early
follicular phase through the midluteal phase (Greenblatt et al., 2000). Further,
cervicovaginal shedding of HIV has been reported to be higher among pregnant women
than it is among non-pregnant women with more advanced HIV disease (Henin et al.,
1993). It has also been questioned whether use of contraceptives can influence the
susceptibility to HIV in females. In particular, the use of progesterone-containing
contraceptives (e.g., Depo-Provera and Norplant) have received attention (Bahamondes et
al, 2000; Cohen, 1996; Miller et al., 2000) after a study showed that monkeys treated with
progesterone implants were at an increased risk for becoming infected with SIV (Marx et
al., 1996). Although it has been assumed that this enhanced SIV infection of the female
genital tract after progesterone treatment was due to thinning of the vaginal barrier (Hild-
Petito et al., 1998; Sodora et al, 1998), other factors such as progesterone-induced
immunomodulation, effects on target cells and receptor expression, or direct effect on virus
transcription cannot be excluded in retrovirus infections. A study by Vassiliadou and
coworkers (1999) suggested that progesterone could have negative effects on chemokine-
mediated recruitment of lymphocytes and monocytes to mucosal epithelia. Further, use of
oral contraceptive with equal levels of progesterone and estrogen induces up-regulation of
the CCR5 chemokine receptor on CD4 T-cells in the cervical epithelium of healthy
women, which could represent an increased risk of HIV-1 transmission via this route
(Prakash et al., 2002). 
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A more direct effect of steroid hormones on retrovirus production is seen in MMTV
infection were progesterone, in addition to glucocorticoids and androgens (but not
estrogens), strongly stimulate the rate of MMTV transcription through the binding of
hormone-receptor complexes to hormone regulatory elements (HRE) in the MMTV LTR
(Beato et al., 1989; Cato et al., 1986; Otten et al., 1988). The strong responsiveness of the
MMTV LTR to steroid hormones has made the MMTV promoter the best-studied model
for investigating the regulation of gene expression by steroid hormones (Beato, 1989;
reviwed in Aranda & Pascual, 2001). General features of steroid-hormone mediated gene
regulation are illustrated in Fig. 8, and are described in the correspondent legend.
Glucocorticoid response elements (GRE) are present in the LTR of several mammalian
retroviruses, and hormonal regulations of virus replication through GRE are reported for
both simple retroviruses  (Beato et al., 1989; Celander et al., 1988; Miksicek et al., 1986)
and complex retroviruses (Niermann & Buehring, 1997; Kolesnitchenko & Snart, 1992;
Mitra et al., 1995; Russo et al., 1999). In HIV, three potential regions are present in the
LTR (Mitra et al., 1995). Another GRE is located in the HIV-1 vif open reading frame
(Sodeyns et al., 1993). The role of these sites in HIV infection is still not clear, and studies
performed in vitro have given diverse results. For example, dexamethasone inhibits LTR-
driven gene expression in some T and B cell lines, but not in monocytic cells (Mitra et al.,
1995). Cortisol and dexamethasone increase HIV-1 production in some lymphoid and
monocytic cell lines, apparently through interaction with response element located in vif
(Sodeyns et al., 1993).
Nelson et al. (1999) suggested that incorporation of hormone response elements in the LTR
might be advantageous for extending the cellular host range of the virus to exploit a number
of endocrine signaling pathways. This may be especially advantageous for the simple
retroviruses which host cells are limited to actively dividing cells (see above). Further, the
presence of HREs implies that physiological changes in the host, including hormonal
fluctuations, can directly influence viral replication. 
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Figure. 8. Steroid hormones and gene regulation. 
Steroid hormones enter cells passively and bind to receptors that are located in the cytoplasm or the
nucleus. The DNA sequences that are recognized by steroid hormone-receptor complexes are
termed hormone response elements (HREs). The first element to be identified was the
glucocorticoid response element (GRE) in the MMTV LTR (Beato et al., 1989 and references
therein).
Glucocorticoids bind to the cytoplasmic form of the glucocorticoid receptor, which is associated
with the heat chock protein, Hsp90 (Pratt & Welsh, 1994). Hormone bound glucocorticoid receptor
dissociates from Hsp90 and is transported to the nucleus, where it binds with high affinity to DNA
sites. Glucocorticoid receptor and other steroid receptors are competent to activate transcription of a
basal promoter in the absence of other transcription factors. GRE mediates gene induction by
glucocorticoids, progesterone, and androgens, but not by estrogens (Beato et al., 1989; Cato et al.,
1986; Darbre et al., 1986; Otten et al., 1988; Scüle et al., 1988). However, the efficiency of steroid
hormone-mediated gene activation depends on several factors including the availability of receptors
and hormones (Archer et al., 1995; Nelson et al., 1999). Further, coactivator complexes and other
transcription factors influence hormone responsiveness of a particular gene (Deroo & Archer,
2001). 
Nucleosomes, which fold chromosomal DNA, contain two molecules each of the core histones
H2A, H2B, H3, and H4. Almost two turns of DNA are wrapped around this octameric core, which
provides a major impediment to transcription. Glucocorticoid receptors (GR) in association with
chromatin-remodelling complex can bind to target sites within promoter regions of genes assembled
as chromatin. This interaction alters the nucleosome architecture to allow binding of other
transcription factors like NF1 (see Fig. 3), that cannot bind an LTR assembled into chromatin
(Archer, et al., 1992, for review on GR-mediated chromatin remodelling see, Deroo & Archer,
2001). Only a single GR-binding site is sufficient for the structural transition to occur (Belikov et
al., 2000). 
DNA
GRE, Glucocorticoid response element 
Steroid - receptor complex
H2N
H2N
COOH
COOH
Glucocorticoid
Inhibitory protein complex    
DNA binding site exposed
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Early virus-host interactions
One of the main challenges that viruses present to the immune system is a kinetic one. The
virus must replicate before the immune response is efficiently mobilized, and this race
between the immune system and the virus in the early stage of infection often determines
the severity of the infection (Bangham & Phillips, 1997). Overall, several studies show that
there is an inverse correlation between plasma viremia and disease progression rate
(described above). Further, the exact timing of peak viremia (see Fig. 6) varies with virus,
route of inoculation, and virus dose inoculated (Table 8). Staprans et al., (1999) suggested
that a less vigorous early virus replication could give the immune response an advantage in
the dynamic host-virus interaction that occurs very early after SIV infection. Studies in the
mouse model of FV infection have also indicated that lower rate of virus spread may allow
a weak immune response time to develop before being overpowered by high level of virus
and virus infected cells (Peterson et al., 2002, and references therein). It is also likely that
the initial phase of infection is the crucial timeframe during which virus clearance or
persistence is determined. Thus, small differences in the initial dynamic relationship
between the host and the virus may influence the course of the infection. For example, virus
factors (e.g., the envelope or LTR) and host factors (e.g., hormones) that exert their effects
before full development of specific immune responses might be critical determinants for the
immediate rate of virus dissemination and susceptibility to infection. 
Exposure to HIV-1 may or may not result in infection, and the AIDS epidemic is
characterized by extreme heterogeneity in the clinical course (see above). Identification of
viral and host factors that determine the susceptibility to HIV infection, or the rate of
progression to disease once infection is established, might lead to novel treatment
paradigms. Unfortunately, the time of infection is often uncertain and the infectious dose
conjectural in HIV infections, so the initial events may easily be missed. Therefore,
investigations of early virus-host interactions must be performed in animal models. 
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Table 8. 
Virus and host factors that may influence the overall course of a retrovirus infection.
COMPLEX VIRUS SIMPLE VIRUS The FIS-2 model
VIRUS FACTORS
inoculum size (dose) Holterman et al., 2000
Quinn et al., 2000
Czub et al., 1992 paper III
route of inoculation/
transmission
Burkhard et al., 2002
Greenier et al., 2001
Herz et al., 2002
Okada et al., 1998
virulence Asjo et al., 1986
Holterman et al., 1999
Czub et al., 1992 papers II- IV
genetic determinants Locher et al., 2003
Coffin et al., 1997*
Fan et al., 1990*
Coffin et al., 1997*
papers I-IV; 
Dai et al., 1994
HOST FACTORS
host genetic
immunity
 
Carrington et al., 1999
Zagury et al., 1998
Paxton et al., 2001
Hasenkrug 1997* paper V
receptors/co receptors Hogan & Hammer 2001b*
age Chakrabarti et al., 2000 Yamaguchi et al., 2001 paper II
sex Gandhi, 2002* Gillespie & Rowson, 1968 papers III-V
hormones
contraceptive use
menstrual cycle
stress hormones/
glucocorticoids
sex-hormones
Prakash et al., 2002
Greenblatt et al., 2000
Corley, 1995 and 1996
Barr et al., 2000
Brabin, 2002
Marx et al., 1996
Smith 2000
Beato et al., 1989
Karande et al., 1975
Archer et al., 1995*
paper IV
paper V
*Reviews. The references listed in the table are representative, not exhaustive
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AIMS OF THE STUDY
The overall objective of the present study was to investigate virus-host interactions in early
murine retrovirus infection, and to define viral and host determinants responsible for
retrovirus-induced erythroleukaemia and immunosuppression. In general, studies of
biological variations can offer important insight into underlying biological mechanisms.
This was used as an experimental approach throughout the study:
Viral determinants 
Since FIS-2 is an immunosuppressive, low oncogenic, variant of the closely related F-
MuLV, comparing the two variants may elucidate the roles of viral genes in the
pathogenesis. At the start of this thesis, six chimeras between FIS-2 and F-MuLV had been
generated (shown in paper I).
 (1) We wanted to use these chimeras as a tool to study genetic (viral) determinant(s)
responsible for the pathogenic properties of FIS-2 (papers I-II).
A major advantage with animal models for virus infections is that we can control for virus
dose and time of infection, and thereby investigate early virus-host interactions that may be
missed in the clinic (e.g., HIV infection).
 (2) We therefore wanted to use our model system to examine whether the infective dose
or early virus dissemination patterns could influence the course of infection (studied in
papers I-III). 
Host determinants
Besides inter-individual host differences, gender-related differences in susceptibility to
virus infections and disease outcome had been reported, but not intensively studied.
 (3) We therefore wanted to study the effects of host gender (sex) on susceptibility to
murine retrovirus infection (papers III-V).
Virus-host interactions
In paper III, we reported that there indeed were gender differences in FIS-2 infection
(susceptibility, early virus dissemination, and immunosuppression). We therefore decided
to investigate this issue further. The main questions we wanted answers to were: 
 (4) Can the presence of a hormone response element (GRE) in the FIS-2 LTR mediate
the sex-differences observed? This was investigated in paper IV. 
 (5) Can physiological conditions of the host, like the hormonal make up, influence the
susceptibility to FIS-2 infection? This was investigated in paper V. 
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SUMMARY OF THE WORK
Paper I
Identification of genetic determinants responsible for the rapid immunosuppressive
activity and the low leukemogenic potential of a variant of Friend leukemia virus,
FIS-2: In this paper we focused solely on viral determinants for pathogenesis. We
attempted to map the genetic factors responsible for the strong immunosuppressive activity
and the low leukaemogenic potential of the F-MuLV variant, FIS-2. Six chimeric viruses
between FIS-2 and F-MuLV cl. 57 were generated and used as experimental tools. The
construction of recombinant viruses was performed before the onset of the present thesis.
Since FIS-2 and F-MuLV have almost identical nucleotide sequences encoding the
immunosuppressive transmembrane protein TM, we were interested in determine viral
factors other than the TM which could underlie the enhanced immunosuppressive
properties of FIS-2. The effect of virus infections (parental and recombinant viruses) on
primary antibody response against a T-cell dependent antigen (SRBC) was used as a
parameter for the immunosuppressive activity in adult NMRI mice. We found that a region
encoding the envelope surface protein (SU) of FIS-2 was responsible and necessary for the
enhanced immunosuppressive activity. This was a novel finding. The immunosuppressive
activity in individual mice infected with F-MuLV or constructs that did not have FIS-2 SU
varied greatly. Our results suggested that the suppressive effect of FIS-2 SU was
overwhelming and dominated over various host genetic factors. In addition, we could not
observe any direct correlation between the number of virus positive cells in the spleen and
immunosuppressive activity. These results indicated that murine retroviruses might exert its
immunosuppressive effect through other mechanisms than direct infection of immune cells
in the spleen.
The leukaemogenic potential of each chimera was studied in newborn mice. Consistent
with studies by others, the low leukaemogenic potential of FIS-2 was determined by the
LTR. As described in the introduction, it is well accepted that sequences within the LTR
contribute to cell-type specific transcription and acts as potentiators of leukaemogenicity.
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Generally, MuLVs with one copy of a DR are thought to have lower transcriptional activity
than MuLVs with two DRs. It was therefore of interest to study the transcriptional activity
of the LTRs from FIS-2 (with one DR) and F-MuLV (with two DRs) in lymphoid cell lines.
Different LTR-chloramphenicol acetyl transferase constructs were made and the CAT
activity was monitored in different cell lines, including T (EL4.IL2 and L691-6), B (CH-1),
monocyte-macrophage (P388D1), and erythroleukaemia (SL9) cells. Although the FIS-2
LTR contained only one DR it had a transcriptional activity either higher than (L691-6,
CH-1 and P388D1) or similar to (EL4.IL2 and SL9) that of the F-MuLV LTR. To our
knowledge, this was the first study showing that the transcriptional activity of a LTR in
vitro did not correlate with the potential leukemogenicity of the corresponding virus in vivo.
It was also shown that deletion of one direct repeat in the F-MuLV LTR caused a decrease
in transcriptional activity in all cell lines except in the L691-6, where no effect was
observed. These results indicated that a few single point mutations in the FIS-2 LTR had
compensated for the loss of one direct repeat.
Paper II
Early dissemination rates of Friend murine leukaemia virus variants correlate with
late pathogenesis: Since the mutations in the FIS-2 LTR did not reduce the transcriptional
activity in vitro, we wanted to examine whether this observation could be confirmed in
vivo. In paper II we also examined whether differences in virus dissemination rates or sites
of replication could explain some of the biological features of FIS-2 and F-MuLV. We
found that erythroblasts were the primary target cells for both F-MuLV and FIS-2, while B-
and T-cells were infected later in the infection. Consistent with the in vitro experiments in
paper I, FIS-2 replicated to similar or higher titres as F-MuLV in vivo. However, we did
observe a delay in the initial spreading of FIS-2. Studies including the chimeras RE3 (FIS-2
LTR in a F-MuLV background) and RE4 (F-MuLV LTR in a FIS-2 background) indicated
that the delay in dissemination was due to mutations in the FIS-2 LTR. The kinetic for early
virus replication correlated with mean latency time for virus induced erythroleukaemia in
mice inoculated as newborn (reported in paper I). Early dissemination rate did also
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correlate with the onset of immunosuppression and erythroleukaemia in adult mice. Early
immunosuppression was induced in a phase with low levels of infected lymphocytes. This
observation indicated once more that mechanisms other than direct infection of immune
cells were involved in murine retrovirus induced immunosuppression. The results in paper
II also confirmed that FIS-2 SU was responsible and necessary for giving FIS-2 enhanced
immunosuppressive activity: The chimera RE4 with F-MuLV LTR and FIS-2 SU induced
both an early and strong, persistent immunosuppression. F-MuLV-induced late
immunosuppression coincided with signs of erythroleukaemia and persistent viremia. FIS-2
induced a more moderate late immunosuppression without persistent viremia or signs of
erythroleukaemia. Overall, our results in paper II indicated that early viral replication is a
prognostic factor in murine retrovirus induced pathogenesis.
Paper III
Gender-related differences in susceptibility, early virus dissemination and
immunosuppression in mice infected with Friend murine leukaemia virus variant FIS-
2: In paper III we used the FIS-2 model to study the effect of host gender (or strictly sex)
on susceptibility to murine retrovirus infection. Our data showed a close relationship
between virus dose, the onset of detectable viremia, and infection in the spleen in young
adult, male and female mice. However, male mice were more susceptible to infection by
low doses of FIS-2 than female mice were. Given equal, high FIS-2 doses we observed that
the levels of virus in serum, bone marrow, and the spleen were initially higher in male
mice. Male mice were also more susceptible to FIS-2 induced immunosuppression. These
results indicated a more efficient virus replication and dissemination in male mice. Such
gender differences were more profound in FIS-2 infection than in F-MuLV infection.
Studies with LTR recombinants indicated that sex-related factors could have a more direct
effect on the activity of FIS-2 LTR than on the activity of F-MuLV LTR. 
Paper IV
A glucocorticoid response element in the LTR U3 region of the Friend murine
leukaemia virus variant FIS-2 enhances virus production in vitro and is a major
SUMMARY OF THE WORK
42
determinant for sex differences in susceptibility to FIS-2 infection in vivo: As described
in the introduction, the nucleotide sequence of the FIS-2 LTR shows a high homology with
that of F-MuLV LTR, except for the deletion of one direct repeat, a few point mutations,
and generation of a glucocorticoid response element (GRE) in the U3 region. GRE(s) can
mediate gene induction by glucocorticoids, mineralcorticoids, progesterone and androgens,
and it has been shown that incorporation of GRE(s) within the LTR can increase the
transcriptional activity of retroviral enhancers. We therefore proposed in paper III that
incorporation of a GRE in the FIS-2 LTR might contribute to the significant sex difference
in FIS-2 infection. In order to investigate this hypothesis, we introduced a single point
mutation in the GRE, and performed comparative studies in NIH 3T3 cells and in male and
female NMRI mice. We found that significantly more virus were produced from NIH 3T3
cells infected with the wild type (wt) FIS-2 than from cells infected with the FIS-2 GRE
mutant, and this difference was further augmented by glucocorticoids. Moreover, the
progesterone/type II glucocorticoid antagonist RU486 inhibited virus production in a dose-
dependent manner. Our previously observed sex-difference in early wt FIS-2 replication
was confirmed in paper IV. In addition, wt FIS-2 disseminated significant faster than FIS-
2 GRE mutant in male mice, but not in female mice. We found no significant difference in
dissemination rate between male and female mice infected by FIS-2 GRE mutant. Based on
these results, we concluded that sex-related factors could influence early FIS-2 replication
via mechanisms involving the GRE.
Paper V
Identification of Friend murine retrovirus infected immune cells and studies of the
effects of sex and steroid hormones in the early phase of infection. In paper V we
investigated further the influence of sex and steroid hormones on early Friend leukaemia
virus dissemination and immune functions. Consistent with former studies we showed that
FIS-2 disseminates faster in male than in female mice. Lymphocyte subsets were more
rapidly infected in males than in females, and some B- and T-cells, including both CD4+
and CD8+ cell subsets, were virus positive in male mice at 11 d.p.i. We could not find any
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significant sex difference in the proportions of erythroblast or B- and T-cells in the spleen.
However, an earlier expansion of the CD8+ cell population was observed in infected male
mice compared to female mice. This expansion paralleled viremia levels. Thus, one
possible explanation for the sex differences in FIS-2 dissemination to lymphocytes,
including CD8+ cells, may be that in male mice high virus replication in the primary target
cells (erythroblasts) and rapid rise in viremia titres are followed by a parallel expansion of
the CD8+ cell subset. Since murine leukaemia viruses only infect dividing cells, antigen-
activated expansion of lymphocyte subsets subsequently increases the number of possible
target cells. 
Viremia and the number of detectable virus positive cells in the spleen declined faster in
females than in males. These post peak declines coincided with a more rapidly generation
of antibodies against virus positive cells. A rise in the CD3e cell subset was most notable
in female infected mice. Further, female derived T-cells responded better to in vitro
mitogen stimuli (Concavalin A) than male derived T-cells. Physiological concentrations of
testosterone or -estradiol did not influence T-cell proliferation, while progesterone and
dexamethasone induced a dose-dependent inhibition. Subsequently, we investigated the
effects of progesterone administration and testosterone/glucocorticoid reduction on early
virus dissemination in female and castrated male mice, respectively. Administration of the
injectable contraceptive Depo-Provera® (depomedroxyprogesterone acetate) did not modify
early FIS-2 production in female mice. Reduction of testosterone level in male castrated
mice had significant impact on both early FIS-2 replication and early F-MuLV replication.
Since F-MuLV does not have a GRE in its LTR, this result showed that androgens could
influence on early virus replication at other levels besides that which involved the GRE.
Castrated mice were notably calmer and less involved in fighting behaviour than male
control mice. In papers IV and V we therefore discussed, in the context of the available
literature and our observations, how behavioural factors like testosterone-dependent
aggression (i.e., inter-male aggression) and subsequent stress-induced elevated levels of
circulating cortisol might influence FIS-2 replication and immune responses during
infection.
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GENERAL DISCUSSION
The studies in the present thesis sought to define virus and host factors that can influence
on the susceptibility to murine retrovirus infection. In addition, we wanted to study possible
correlations between events of early infection and subsequent disease progression. For an
extensive discussion of the major findings, the reader is referred to papers I-IV. The
following section will give a general discussion concerning 1) some methodological
aspects; 2) the course of FIS-2 infection; 3) determinants responsible for erythroleukaemia;
4) determinants responsible for immunosuppression; and, 5) does sex matter?
I: Methodological considerations
In vivo studies: The mouse model.
 Infection of macaques with SIV is the major model in which to study the early phase of
immunodeficiency retrovirus infection. However, problems with this model includes the
limited number of available monkeys (Choen, 2001), the genetic heterogeneity of the
available animals, the lack of certain immunological reagents, costs, and ethical
considerations (Joag, 2000). Thus, fundamental concepts in retroviral immunology have to
be defined in other ways such as in small animal models.
 As described in the introduction, complex retroviruses encode and express additional
proteins, and these proteins allow direct control over functions that in simple retroviruses
are provided by the host. This additional control may be advantageous in dealing with the
host immune responses; complex retroviruses infect adult, immunocompetent animals
much more frequently than do simple retroviruses (Coffin et al., 1997). Nevertheless,
although complex retroviruses and the hosts they infect are different from the simple
retroviruses, many structural and functional properties of complex retroviruses are common
to all retroviruses, and initial studies on the “AIDS virus” benefited greatly from existing
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knowledge on oncoretroviruses (see Table 3, and the introduction). Since the most
fundamental features of complex and simple retroviruses are comparable, murine
retroviruses offers inexpensive and less ethical controversial systems for studying general
virus-host aspects of the early phase in retrovirus infections (Hasenkrug et al., 1997,
Morrison et al, 1986; Mosier et al., 1996, Soldaine et al., 1989). Further, mouse models
have a special appeal because of (i) the ability to work in genetically defined mouse strains,
transgenic, and knockout animals; (ii) the immune system in mice is known in detail and
can easily be manipulated; and (iii) there are a variety of mouse immunological reagents
available. 
Traditionally, random-bred laboratory animals have been said to have a degree of variance
similar to what would be expected in the human population. The initial goal for the “FIS-2-
project” was to develop a murine retroviral immunosuppressive system shearing central
features with HIV-1 infection in humans. For that reason, an outbred mouse strain was
chosen as model organism, and the low oncogenic and immunosuppressive variant of F-
MuLV was isolated from a FV infected female NMRI mouse (Faxvaag et al., 1993a).
Murine leukaemia virus can be designated as either N-tropic or B-tropic, depending upon
whether it replicates more efficiently on NIH Swiss (Fv-1n) or BALB/c (Fv-1b) fibroblast
cells, respectively. A third group of MuLVs replicates equally well on both BALB/c and
NHI Swiss fibroblasts, and they are designated NB-tropic (Troxler et al., 1980). The
prototype F-MuLV cl. 57 used in the present thesis is NB-tropic, while FIS-2 is N-tropic.
Thus, FIS-2 does not replicate well in the commonly used inbred BALB/c mouse strain
(data not shown). Therefore, outbred NMRI mice were used throughout the study. 
Generally, the major disadvantage with outbred stocks is the necessity for more animals in
the experiments. However, outbred NMRI mice are genetically variable to the extent that
all individuals are genetically unique, but they tend to be relatively uniform in comparison
with the variability within the species. Further, all NMRI mice have the same genotype of
the MHC (H-2q) (data sheet about NMRI mice supplied by Bomholdtgaard Breeding
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Research Center). Nevertheless, pronounced inter-individual differences were observed in
viral load, immunosuppression, and anti-virus responses in the populations examined
(papers I-V). These findings demonstrate the significance of host-factors in murine
retrovirus infection. 
In vitro studies: Cell lines and primary cell cultures.
 The ultimate test of pathogenic potential involves induction of disease in animals. Further,
virus-host interactions must necessarily be studied in vivo. However, the ability to grow and
quantitate retroviruses in vitro is important for several reasons, including the possibility to
characterize viral mutants. In paper IV the replication of wt FIS-2 was initially compared
to FIS-2 GRE mutant in vitro. Since more virus were indeed produced from NIH 3T3 cells
infected with wt FIS-2 than from cells infected with FIS-2 GRE mutant, the virus
replications were subsequently compared in vivo. Thus, by combining experiments in vitro
and in vivo, the number of animals used in a study can be reduced (which is an important
goal in all studies involving experimental animals). 
Many cell types can be used to grow and assay retroviruses in vitro. For studies of murine
retroviruses, immortalized rodent cell lines such as 3T3 cells have proven particular useful
(Coffin et al., 1997). However, fibroblastoid cells are usually not directly involved in
retrovirus induced disease. We have therefore also used primary cultures of normal
hematopoietic cell. Previously, an in vitro immunization culture system of splenic cells
isolated from FIS-2 infected mice was used to study derangements of cytokine production
(Faxvaag et al., 1995). In paper V, a similar culture system was utilized to compare T-cell
functions in male and female mice, and examine the influence of steroid hormones on
mitogen induced T-cell proliferation. It was also our intention to use primary cell cultures
to examine whether steroid hormones could influence FIS-2 production. However, as
shown in papers II, III, and V, the amount of virus infected B– and T-cells are low in FIS-
2 infected mice, making this approach rather cumbersome. In paper IV, NIH 3T3 cells
were therefore used to study whether hormones could induce FIS-2 production.
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 NIH 3T3 cells were also used to quantify viral load in serum and organs, by co-culturing
dilutions of e.g., serum or splenocytes with the cell-line. Such end-point dilution procedure
is undeniably time consuming and cumbersome (described in papers III and IV).
However, by this approach we could detect productive infection in e.g., the spleens.
Further, the assay is rather sensitive, with detection limits on 50 IU per ml serum and one
productively infected cell per 200 000 splenocytes. In comparison, the limit of HIV RNA
detection in currently available assays is 50 copies per ml plasma (Richman, 2001).
Viruses used
Due to the low fidelity of the reverse transcriptase, retrovirus stocks amplified in cell
culture or in vivo exist as quasispecies. Such high degree of variation poses problems of
reproducibility and standardization. In contrast, a molecular cloned virus can be maintained
as a DNA provirus in plasmids or lambda phages, and can be amplified with minimal or no
changes. Molecular clones are therefore preferable to uncloned viruses for most
experimental uses. In the present thesis, molecular cloned viruses (Dai et al., 1994) were
used in all experiment. Virus stocks were prepared and titrated from supernatants collected
from transfected cells as described in paper I. The stocks were dispensed into small
aliquots and stored at -80oC until the start of each experiments. If possible, virus stock from
the same “batch” was used in most studies. However, in papers II and III, two different
stocks of FIS-2 were used in the experiments. We did not observe any striking difference in
the dose-responses. Nevertheless, one should be cautious with direct comparison of the
doses between the experiments. 
As described in the introduction, chimeric viruses created by recombining segments of two
strains of the same virus (e.g., Friend MuLV and Moloney MuLV) have proven very useful
in defining amino acid or nucleotide sequence responsible for various biological properties.
At the start of the present thesis, six chimeric viruses between FIS-2 and the prototype F-
MuLV clone 57 had been generated (shown in paper I). Briefly, in the chimera RE1 and
RE2 a fragment containing the whole gag and part of the pol gene was switched between
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FIS-2 and F-MuLV. RE3 got FIS-2 LTR in a F-MuLV background and RE4 got F-MuLV
LTR in a FIS-2 background. RE5 received FIS-2 LTR, gag and part of the pol. To study the
pathogenic effect of the FIS-2 env gene, RE6 received a fragment of FIS-2 containing most
of the env gene of FIS-2 in the F-MuLV background. In paper I, all chimeras were used to
identify viral determinants responsible for virus induced erythroleukaemia and
immunosuppression. In papers II and III, the chimeras RE3 and RE4 were used to
examine the influence of FIS-2 LTR versus F-MuLV LTR on early virus replication and
dissemination. Further, in paper IV we introduced a single point mutation in the
glucocorticoid response element (GRE) presented in the FIS-2 LTR U3 region. It should be
noted that these chimeras and the mutated virus do not constitute new models, but are
specific application within the framework of the FIS-2 model.
The recombinant DNA techniques were performed by standard procedures, as described in
papers I and IV. Since this (excellent) work was performed by my co-authors, no detailed
description and discussion about this part of the study will be given here. However, when
comparing virus variant with subtle differences, the stability of the changes performed have
to be confirmed. In paper I, the chimeric viruses were confirmed by Southern blot analysis
of Hirt extracts prepared from NIH 3T3 cell infected with the chimeric stocks. The stability
of the single nucleotide exchange in the GRE core sequence after in vitro and in vivo
replication was confirmed by RT-PCR and subsequent sequencing of the virus genome
isolated from in vitro-infected NIH T3T cell culture supernatants and serum from infected
mice, respectively (paper IV). 
Detection of immunosuppressive activity.
The effect of viral infection of the primary antibody response against SRBC was previously
used as a parameter of immunosuppressive activity of the FV (Bendinelli et al., 1985;
Ceglowski & Friedman, 1970; Mortensen et al., 1974) and the primary stock of the FIS
variant (Faxvaag et al., 1993a). This test system was therefore also used to examine the
degree of immunosuppression in FIS-2 infected mice (Dai et al., 1994; papers I-III). The
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generation of an immune response to SRBC requires the interaction of T-cells, B-cell, and
macrophages, and the assay, in which the number of B-cells producing anti-SRBC is
determined by using a slide monolayer technique, is described in detail in paper I. 
II: The course of FIS-2 infection.
 
Taken together, results from papers I-V show that the course of FIS-2 infection in adult
mice has many features comparable to the courses in complex retrovirus infections. Similar
to HIV infection (see Figure 6), the viremia peaks quite rapidly in the acute phase, and
decline as immune responses develop and attain control over the infection. The kinetics of
virus replication, immunosuppression, and some immune responses during FIS-2 infection
in female NMRI mice are illustrated below:
Figure 9. A schematic diagram of events occurring after FIS-2 infection in female NMRI mice.
The figure is based on results presented in papers I-V. The dotted lines indicate unpublished or
tentative observations. See text for details.
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In FIS-2 infected mice, peak viremia were reached 5-11 dpi, depending on virus dose, virus
variants, and host sex (papers II and IV). This event was followed by a decline in viremia
that coincides wih the appearance of antibodies against virus infected cells (papers IV and
V). In female mice the anti FIS-2 response was shown to be highly efficient, keeping the
level of cell-free virus in the blood (viremia) below detectable limit, in spite the fact that
productive virus infection was detected in the spleens during the same period of late
infection (paper II). We observed expansions of the CD8+ and CD3+ cell subsets in the
spleen during the early phase of infection (paper V), indicating involvement of cell-
mediated immune responses in the initial control of FIS-2 infection. However, and
extensive analyze of the immune responses against FIS-2 was not performed in the present
study. Therefore, more investigation is needed to elucidate important immune parameters in
FIS-2 infection. 
FIS-2 induced a pronounced immunosuppression against SRBC at 14 dpi. The kinetic or
severity of the immunosuppression was influenced by infective dose (paper III) and
replication rate (papers II-III). An interesting phenomenon was noted in a study of the
humoral immune responses in female mice inoculated with high FIS-2 dose (Standal et al;
manuscript in preparations): Initially, high titer serum levels of neutralizing antibodies and
antibodies directed against viral membrane proteins on infected cells were detected.
However, as infection proceeds, these levels were drastically reduced (see Fig. 9). Further,
the degree of the immunosuppression that developed was unrelated to the level of
protective antibodies. Thus, antiviral antibodies does not protect against development of
immune deficiency and antiviral humoral response, when initiated, is not significantly
interfered by the immunosuppression that starts to develop the first week of infection. The
FIS-2 induced immunosuppression was partly restored after primary infection, but seemed
to become subsequently more severe. 
The major clinical differences in FIS-2 versus F-MuLV cl. 57 inoculated adult mice were
observed in the early and late phases of the infections. F-MuLV disseminated somewhat
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faster than FIS-2, and induced a rapid, but transient and mild immunosuppression (paper
II). At 14 dpi, all FIS-2 infected mice were totally immunosuppressed; whereas only 10%
of the F-MuLV infected mice were immunosuppressed at this point (paper I). While FIS-2
seemed to be efficiently down regulated by the host immune system, some of the F-MuLV
inoculated mice had detectable viremia 2-4 months post inoculation (paper II). Further, in
contrast to FIS-2, several F-MuLV inoculated mice developed gross splenomegaly in this
period. Thus, only FIS-2 induced late immunosuppression without any signs of
erythroleukaemia in adult mice (paper II).
III: Determinants responsible for erythroleukaemia.
LTR and virulence
Consistent with previous studies (described in the introduction), the deletion of one direct
repeat in the LTR was responsible for the long latent period of erythroleukaemia induced
by FIS-2 in mice inoculated as newborne. Surprisingly, the mutations in the FIS-2 LTR did
not seem to reduce transcriptional activity in vitro (paper I), and FIS-2 was shown to
replicate to similar or higher titre than F-MuLV in the in vivo experiments (paper II). To
our knowledge, this was the first evidence that high transcriptional activity of an LTR in
vitro, or replication capacity in vivo, did not correlate with the potential leukemogenicity of
the corresponding virus. However, we showed a correlation between early virus
replication rate and subsequent virus induced erythroleukaemia. Initial virus dissemination
was determined by the LTR (paper II). The primary target cells for both FIS-2 and F-
MuLV seemed to be erythroblasts, while B- and T-cells were infected later in the course of
infections. Thus, the biological difference between FIS-2 and the prototype F-MuLV cl. 57
was not due to replication in different target cells. 
Age and viral load
Most studies of age-related changes in susceptibility to murine retrovirus have focused on
the progression from young age to adulthood. During this period, mice generally become
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more resistant with increasing age (Hoffmann et al., 1984). This phenomenon is thought to
reflect that young and adult mice are more immunocompetent than neonatal mice are.
However, some reports have indicated that newborn mice are less immunology immature
than previously thought (Forsthuber et al., 1996, Ridge et al., 1996), and that
immunological responses in newborn mice are partly determined by the antigen level
(Sarzotti et al., 1996). The influence of the infecting virus dose in Friend virus (FV)
infection has been previously investigated: Li et al. (1987) found that, given in high doses
(from 105 PFU), a 100-fold dilution of input increased the latent period for erythroleukemia
induction by 10 days (from 55 to 65 days). Chesebro and coworkers (1990) showed that in
mouse strains with H-2 Dd/b genotype the size of FV inoculum had strong influence on the
incidence of spontaneous recovery from leukaemia in adult mice. Their experiments
suggested that the anti-FV response was highly dependent on the initial dose of virus.
Sarzotti et al. (1996) showed with another murine system that high doses of Cas-Br-M
murine leukaemia virus induced a non protective TH2-type response in newborn mice,
while a very low dose of virus induced a protective cytotoxic T lymphocyte (CTL)
response. A few studies have also studied the changes from adulthood to old age. In most
species, there are age-dependent declines in the immune responses, which may result in an
increased susceptibility to infectious agents (Hirokawa 1994). However, studies by
Yamaguchi et al., (2001), indicated that old target cells were more refractory to Friend
leukaemia virus induced leukemogenesis than young target cells. Although the precise
mechanism of this observation was not clearly shown, the authors suggested that old target
cells might have lower proliferative potential and thus had less frequent chance for
retroviral infection. 
Since newborn mice have a substantial erythropoesis in bone marrow, liver, and spleen, we
proposed in paper II that a high number of replicating target cells (i.e., erythroblasts) in
newborn mice influence the susceptibility to Friend murine leukaemia infection. Further,
our results indicated that the rate of replication or dissemination within the first few days of
infection is a major determinant of subsequent pathogenesis. Our findings favor the view
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that a high level of virus replication is required only transiently during the early pre-
leukaemia stages of disease, and that the rate of infection of target tissue is more relevant to
disease induction than the level of virus replication per se (Evans et al., 1987). As described
in the introduction, since murine leukaemia virus does not encode an oncogene and cause
tumours by integrating near cellular oncogenes and activating or altering their transcription,
the more cells that become infected, the greater the likelihood that an oncogenic integration
will occur.
IV: Determinants responsible for immunosuppression
Initial virus dissemination rate or the virus dose inoculated also influenced virus-induced
immunosuppression (papers II and III, respectively). Such a correlation between viral load
and immune dysfunctions has been previously reported in FV infection (Bendinelli et al.
1985; Ceglowski & Friedman, 1970). The observation that viral uninfectious particles, and
especially a conserved hydrophilic region of the TM protein, had immunosuppressive
properties has been suggested as a possible explanation for the correlation between viral
load and immunosuppression in retrovirus infection (Denner 1998). However, since TM is
almost1 unchanged in FIS-2 (Dai et al., 1994), the difference in immunosuppressive
properties between FIS-2 and F-MuLV must be determined by other sequences than TM. In
papers I and II, we showed that the major determinant for the enhanced
immunosuppression of the primary antibody response was the FIS-2 SU portion of the virus
envelope. SU is composed of two domains that are linked by a short, proline-rich, “hinge”
region (Lavillette et al., 1998). In the SU of Friend MuLV the N-terminal 235 residues
before the proline-rich region form a discrete domain (receptor binding domain, RBD) that
binds to its receptor, murine CAT1 (mCAT1), with high affinity and 1:1 stoichiometry
(Battini et al., 1992; Battini et al., 1995; Davey et al., 1997; and see Fig. 10). Among the
22 amino acid changes found in the FIS-2 SU compared to the F-MuLV SU, 10 were
                                                
1 There is one mismatch of an extra glutamine residue located in the carbocyl-terminal end of the FIS-2 TM protein.
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shown to accumulate in a region of 100 amino acids (200-300), with three amino acids
changes in region 282-290. Computer analysis showed that such changes gave rise to
higher hydrophilicity in this region, which overlaps with the proline-rich region (Dai et al.,
1994). 
Figure. 10. The envelope protein of Friend MuLV and receptor binding. The viral membrane
containing the Env protein is at the top. Env is depicted with the receptor binding domain, RBD
(oval) connected by the proline-rich region (curved line) to the C-terminal segment (light shaded
rectangle). The transmembrane domain (dark shaded rectangle) is connected to the C-terminal
segment by a disulfide bond. The cell membrane containing the F-MuLV receptor (mCAT1) is at
the bottom. From Barnett & Cunningham (2001). 
Initially, we hypothesized that the difference in immunosuppressive properties between
FIS-2 and F-MuLV clone 57 were due to different target cells infected by the two virus
variants. However, in paper II we showed that erythroblasts were the primary target cells
for both FIS-2 and F-MuLV in adult mice, while B-and T-cells were infected later. Our
studies also showed that immunosuppression was induced in a phase with low levels of
lymphocytes infected. This observation indicated that other mechanisms than direct
infections of immune cells were involved in FIS-2 induced immunosuppression. Thus, it is
still enigmatic how the FIS-2 SU envelope protein enhances the immunosuppressive
properties of FIS-2.
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More generally, soluble immune-regulatory factors induced by the virus infection itself or
virus proteins (e.g., SU?) are known to constitute some of the immune cell abnormalities in
retrovirus induced immunosuppression. It has been suggested that downregulation of
immune function may be related to the increased production of interleukin (IL)-4, IL-10,
and transforming growth factor- (TGF-) by T helper (TH) cells of the TH2 subset; all
three cytokines are known to inhibit activation of macrophages and TH1 cells mediated by
interferon- (Joag & Narayan, 1993; Sher et al., 1992). 
There are indeed multiple derangements of cytokine homeostasis in FIS-variant2 infected
adult mice: A severe depression of immune reactivity towards neoantigens develops
concomitant with suppression of IL-2 and TNF- production and an increased production
of TGF- (Faxvaag et al., 1993b, Faxvaag et al., 1995). These previous studies showed that
the virus-induced immunosuppression involved both T- and B-cell functions. Disturbed
cytokine homeostasis and a switch to a TH2 immune cell response in infected mice may
explain some of the observed changes in immune cell function (Faxvaag et al., 1995).
Further, production of TGF-, a peptide with the ability to suppress immune cell functions
(Letterio & Roberts, 1998), might be an important factor (Faxvaag et al., 1993b). 
An intriguing feature of TGF-1 is that its inhibitions are not simply limited to the initial
activation of the naïve T-cells: Lúdvíksson et al. (2000) found that TGF- had a carry-
over effect such that T-cells re-stimulated in secondary cultures were less reactive both
with respect to proliferation and TH1 or TH2 cytokine secretion, even when they were
stimulated secondarily in the absence og TGF-1. Thus, strong stimulation of TGF-
production early in the infection could induce a long lasting immunosuppression (for
review on regulation of immune response by TGF-, see Letterio & Roberts, 1998).
Exclusive up-regulated expression of TGF- from LP-BM5 MuLV infected stromal cell
lines has been associated with impaired hematopoiesis (Gallicchio et al., 1996).
                                                
2 Isolated from spleen extract, not to be confused with the molecular cloned FIS-2.
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Immunosuppression by TGF- has been more clearly indicated in FV infected mice were
chronic FV infection induced expansion of CD4+ regulatory T-cells that suppressed the
proliferation of CD8+ T-cells in vitro by means of mechanisms involving TGF- but not
IL-2 and IL-10 (Iwashiro et al., 2001).
Another possible producer of TGF- might be (virus-infected) erythroblast. Immature
erythroide cells can suppress humoral immune response induced by both thymus dependent
and thymus independent antigens. This immunoregulatory effect are mediated, at least in
part, by soluble factors that can suppress B-cell proliferation (Mitasov et al., 1991),
including release of TGF- (Sennikov et al., 1996; Seledtsov et al., 1998). In a preliminary
study we have identified production of TGF- in spleen reed pulpa as well as in spleen
white pulpa from FIS-2 infected mice (data not shown). It would be of interest to determine
whether the level of TGF- production correlates with early viral load and/or if production
of soluble immune-regulatory factors can be induced by virus infection of erythroide
progenitors or activated by the SU portion of the FIS-2 envelope.
V: Does sex matter?
Besides inter-individual differences in the NMRI mice studied, we observed that host
gender influenced the susceptibility to FIS-2 infection. Our results indicated a more
efficient FIS-2 replication and dissemination in male mice compared to female mice
(papers III-V), with subsequent more rapid immunosuppression induced (papers III and
V). Male mice also showed impaired immune responses compared to female mice (papers
IV and V). The presence of a GRE in the FIS-2 LTR enhanced initial virus dissemination
in male mice, and was shown to be a major determinant for the observed sex differences
(paper IV). 
Are there any resemblances to these observations in humans? The answer is indeed yes.
Despite reports to the contrary (Bush et al., 1996, Fang et al., 1997, Kalish et al., 2000,
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Moore et al., 1999), several reports have suggested that early plasma HIV-1 RNA load
(viremia) is lower in women than in men: Farzadegan et al., (1998) showed that at a
common threshold of CD4 cell count women had median viremia 38% to 65% of those in
men. Other studies have shown sex difference at or near the time of seroconversion (Evans
et al., 1997, Lyles et al., 1999, Sterling et al., 1999). The difference seemed to decrease
over time (Evans et al., 1997, Sterling et al., 1999), and no difference in viral load in men
and women with very advanced HIV disease have been found (Kalish et al., 2000). 
In a critical epidemiological review of the available evidence concerning whether patient
sex affect HIV virus levels, the authors demonstrated that there was a consistent association
between female sex and lower HIV RNA level, even after adjustment for possible
confounders such as age, race, mode of virus transmission, and antiretroviral therapy use
(Gandhi et al., 2002). A meta-analysis of published studies has also confirmed that women
have lower plasma HIV RNA levels than men with similar CD4 lymphocyte counts and
stage of disease (Napravnik et al., 2002). Why women seem to progress to the clinical end
points of AIDS and death as quickly as men, despite having lower levels of viremia,
remains unexplained. Further, the biological mechanism for the observed gender effect on
HIV RNA levels is unclear.
Gender differences in HIV-1 diversity at the time of infection has also been reported: Long
et al., (2000) found that women from Kenya were often infected by multiple virus variants,
whereas men from Kenya were not. An Institute of Medicine report called “Exploring the
Biological Contributions to Human Health: Does Sex Matter?” (Wizemann & Pardue,
2001) emphasized the impact of sex differences on disease from the cellular to the societal
level. Overall, recent reports have shown that it is important to be cautious in extrapolating
data obtained from men to understand HIV transmission and pathogenesis in women.
Gandhi et al. (2002) suggested that because manifestations of HIV infections stem from the
interplay between viral and host factors, sex differences in e.g., immune modulation will
likely play instrumental roles in determining the course of disease.
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In conclusion, the present study shows the following main results:
 (1) Mutations in the FIS-2 LTR had made the virus variant less oncogenic, while
mutations in the envelope surface protein (SU) gave FIS-2 enhanced
immunosuppressive properties compared to the prototype F-MuLV cl. 57. 
 (2) Early viral dissemination rates of Friend murine leukaemia virus variants correlated
with late pathogenesis. Thus, early viral replication seemed to be a prognostic factor
in murine retrovirus infection. 
 (3) Host sex influenced susceptibility to FIS-2 infection, male mice being more
susceptible than females. 
 (4) FIS-2 replication was enhanced by the presence of a hormone response element
(GRE) in the LTR, and this element was a major determinant responsible for the
observed sex differences in susceptibility, early virus dissemination, and virus-
induced immunosuppression. 
 (5) Studies in vitro and in vivo suggested that stress hormones, like glucocorticoids,
could influence retrovirus infection, directly through enhanced virus replication,
and/or indirectly through regulation of immune responses. 
Overall, our studies indicated cumulative effects of viral factors (e.g., LTR, GRE), sex, and
hormones on murine retrovirus infections, and the hormonal background of the host might
influence virus productions, as well as anti virus responses. However, the severity of
immunosuppression in FIS-2 infected mice is determined by some virus factors, like the SU
portion of the FIS-2 envelope protein, which is dominant over other viral factors as well as
various genetic factors of individual mice. More research is needed to elucidate how the SU
influence immunosuppression and how the GRE determines sex-differences in early FIS-2
dissemination.
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Future perspectives
The scale of the HIV/AIDS epidemic has exceeded all expectations since its identification
20 years ago. Globally, an estimated 42 million people are currently (end 2002) living with
HIV, and some 20 million people have already died (derived from http://www.unaids.org).
Further, just as the spread of HIV has been greater than predicted, so too has its impact on
social capital, population structure, and economic growth (reviewed in Piot et al., 2001;
Weiss, 2001). Highly active antiretroviral therapy (HAART) can block replication of HIV-
1 and is associated with an improvement in the ability to resist opportunistic infections.
However, because HIV-1 can establish a latent infection in long-lived memory CD4+ T-
cells, current HAART cannot eradicate HIV-1 (Finzi et al., 1999). Therefore, life long
HAART is necessary. Such therapy has several limitations, including long-term side effects
and the requirement for strict adherence to the medication to prevent viral resistance
(reviewed in Carr & Cooper, 2000; Richman 2001). Moreover, the current treatments are in
many respects only for the economically privileged, and most developing countries cannot
afford the drugs as well as the necessary monitoring and support of HIV care (Moore, 2000;
Forsythe, 1998). Thus, new strategies to combat HIV are urgently needed.
The major challenge is to elucidate which types of immune responses are required for
protection from retroviral infections. The FV mouse model has recently proven very
valuable in this respect (reviewed in Hasenkrug and Dittmer, 2000). The FIS-2 model
offers another approach to study retrovirus-host interactions in a small animal model. The
major advantages with this model system are: (i) FIS-2 is immunosuppressive but low
oncogenic. (ii) FIS-2 is molecular cloned and a well-defined virus. (iii) The course of FIS-2
infection shows some resemblance to the course of HIV infection; and (iv) in female mice,
the anti FIS-2 response is highly efficient. Thus, the FIS-2 model may also be used to
investigate basic mechanisms of retroviral immunity. 
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APPENDIX
i
Glossary of Virology:
Adapted from http://www.tulane.edu/~dmsander/WWW/MBChB/VirGloss.html,
http://www.virology.net/ATVHIVGlossary.html , and Cann (2001).
Acquired immunodeficiency syndrome (AIDS): The most severe manifestation of infection with
the human immunodeficiency virus (HIV). The Centers for Disease Control and Prevention list
numerous opportunistic infections and neoplasms (cancers) which, in the presence of HIV infection,
constitute an AIDS diagnosis. In addition, a CD4+ T-cell count below 200/mm3 in the presence of
HIV infection constitutes an AIDS diagnosis. The period between infection with HIV and the onset
of AIDS averages 10 years in the USA. People with AIDS often suffer infections of the lungs,
brain, eyes and other organs, and frequently suffer debilitating weight loss, diarrhoea and a type of
cancer called Kaposi's sarcoma. Even with treatment, most people with AIDS die within two years
of developing infections or cancers that take advantage of their weakened immune systems. 
Acute infection: Relatively brief infections, i.e., a few days to a few weeks, following which the
virus is usually eliminated completely from the body by the immune system (e.g., an infection
causing disease with a sudden onset, severity and (often) short course). As related to HIV infection:
Once the virus enters the body, HIV infects a large number of CD4+ T-cells and replicates rapidly.
During this acute or primary phase of infection, the blood contains many viral particles that spread
throughout the body, seeding themselves in various organs, particularly the lymphoid tissues.
Chronic infection: The converse of acute infections, i.e., prolonged and stubborn. Caused by
viruses that are able to persist in the body. 
Complex retroviruses: Include lentiviruses that have multiple splice donors in the genome. This
give rise to complex patterns of mRNA and a variety of gene products (up to six in addition to gag,
pro, pol and env proteins in HIV and SIV), at least one of which has a virus-specific trans-
activating function (see Transcription). HIV-1 DNA integration can take place in non-dividing cells.
Envelope:  In virology, a protein covering that packages the virus's genetic information. The
envelope of HIV is composed of two layers of fat-like molecules called lipids taken from the
membranes of human cells. Embedded in the envelope are numerous cellular protein, as well as
mushroom-shaped HIV proteins that protrude from the surface. Each mushroom is thought to
consist of a cap made of four glycoproteinmolecules called gp120 and a stem consisting of four
gp41 molecules embedded in the envelope. The virus uses these proteins to attach to and infect
cells. 
Fusion protein: The protein(s) on the surface of a virus particle responsible for fusion of the virus
envelope with cellular membranes.
Gene expression: An important stage of viral replication at which virus genetic information is
expressed: one of the major control points in replication.
Genome replication: The stage of viral replication at which the virus genome is copied to form
new progeny genomes.
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Inoculation:  In the present thesis, the introduction of a substance (inoculum; e.g., virus) into the
body to produce the disease or condition associated with the substance.
Latency: The period when e.g., a virus is in the body and not producing any ill effects.
Latent infection: Viruses that are able to down-regulate their gene expression can establish a truly
latent state, i.e., with strictly limited gene expression and without ongoing virus replication. Latent
virus infections typically persist for the entire life of the host.
Molecular epidemiology: The use of nucleotide sequence information to study the diversity and
distribution of virus populations.
mRNA: Messenger RNA, translated on ribosomes to produce proteins.
Mutation:  In biology, a sudden change in a gene or unit of hereditary material that results in a new
inheritable characteristic. In higher animals and many higher plants, a mutation may be transmitted
to future generations only if it occurs in germ or sex cell-tissue; body cell mutations cannot be
inherited. Changes within the chemical structure of single genes may be induced by exposure to
radiation, temperature extremes, and certain chemicals. The term mutation may also be used to
include losses or rearrangements of segments of chromosomes, the long strands of genes. Drugs
such as colchicine double the normal number of chromosomes in a cell by interfering with cell
division. Mutation, which can establish new traits in a population, is important in evolution. As
related to HIV: HIV mutates rapidly. During the course of HIV disease, viral strains may emerge in
an infected individual that differ widely in their ability to infect and kill different cell types, as well
as in their rate of replication. Strains of HIV from patients with advanced disease appear to be more
virulent and infect more cell types than strains obtained earlier from the same individual. 
Neonatal: Concerning the first four weeks of life after birth (in humans).
Neutralization: Blocking of virus infection by antibodies; also, an assay that measures this.
Open reading frame: protein-encoding domain within a gene.
Penetration: The stage of viral replication at which the virus genome enters the cell.
Persistent infection: Infections in which ongoing virus replication occurs, but the virus adjusts its
replication and pathogenicity so as to avoid killing the host. They differ from chronic infections in
that whereas in chronic infections, the virus is usually eventually cleared by the host (unless the
infection proves fatal), in persistent infections, the virus may continue to be present and to replicate
in the host for its entire lifetime.
Receptor: A specific molecule on the surface of a cell that is used by a virus for attachment.
Release: The stage of viral replication at which virus particles escape the infected cell.
Seroconversion: The development of antibodies to a particular antigen. When people develop
antibodies to HIV or an experimental HIV vaccine, they "seroconvert" from antibody-negative to
antibody-positive.
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Simple retroviruses: Includes Murine leukaemia viruses. Simple retroviruses have what is called a
“simple lifestyle” characterized by the presence of at the most one coding region in addition to
those encoding the common virion proteins encoded by gag, pro, pol and env. F-MuLV DNA
integration is currently thought to occur only after the nuclear membrane breaks down during
mitosis.
Splenomegaly: An enlarged spleen.
Sterilizing immunity: An immune response that eliminates an infection.
Subcutaneous: Beneath or introduced beneath the skin (e.g., subcutaneous injections).
Susceptible: Vulnerable or predisposed to a disease.
Titer (also "titre"): A laboratory measurement of the amount (or concentration) of a given
compound in solution.
Transcription: The process of constructing a messenger RNA molecule using a DNA molecule as
a template with the resulting transfer of genetic information to the messenger RNA. As related to
HIV: The process by which the provirus produces new viruses. RNA copies called messenger RNA
must be made that can be read by the host cell's protein-making machinery. Transcription is
facilitated by cellular enzymes, including RNA polymerase II. The viral genes may partly control
this process: tat, for example, encodes a protein that accelerates the transcription process by binding
to a section of the newly made viral RNA. 
Transformation (e.g., cell transformation by virus): A change in the morphological, biochemical,
or growth parameters of a cell. Transformation may or may not result in cells able to produce
tumours (neoplastic transformation). Oncogenesis is a complex, multi-step process in which cellular
transformation may be only the first, although essential, step along the way.
Transmission:  In the context of HIV disease: HIV is spread most commonly by sexual contact
with an infected partner. The virus can enter the body through the mucosal lining of the vagina,
vulva, penis, rectum, or the mouth during sex. The likelihood of transmission is increased by factors
that may damage these linings, especially other sexually transmitted diseases that cause ulcers or
inflammation. Studies of SIV infection of the genital membranes of nonhuman primates suggest
that the cells known as mucosal dendritic cells may be the first cells infected. Infected dendritic
cells may migrate to lymph nodes and infect other cells. HIV also is spread through contact with
infected blood, most often by the sharing of drug needles or syringes contaminated with minute
quantities of blood containing the virus. Children can contract HIV from their infected mothers
either during pregnancy or birth, or postnatally, via breastfeeding. Current research indicates that
the AIDS virus may be 100 to 1000 times more contagious during the first two months of infection,
when routine AIDS tests are unable to tell whether people are infected.
Tropism: The ability of a virus to infect specific cells or tissue types.
Type C retrovirus: Simple retrovirus, frequently associated with cancer. 
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Uncoating: The stage of viral replication at which structural proteins are lost and the virus genome
is exposed to the replication machinery.
Variant: A virus whose phenotype differs from the original wild type strain, but were the genetic
basis for the difference is not known.
Viral burden (viral load): The amount of virus in the circulating blood. Monitoring a person's
viral burden is important because of the apparent correlation between the amount of virus in the
blood and the severity of the disease; sicker patients generally have more viruses than those with
less advanced disease. 
Viremia: The presence of virus in the bloodstream.
Virions: Structurally mature, extracellular virus particles.
Virus attachment protein: The protein on the surface of a virus particle responsible for binding
the receptor.
(+) sense RNA (plus-sense RNA): A virus with a single-stranded RNA genome of the same
polarity ('sense') as mRNA.
(-) sense RNA (minus-sense RNA): A virus with a single-stranded RNA genome of the opposite
polarity ('sense') as mRNA.
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Glossary of Immunology:
Adapted from http://www.tulane.edu/~dmsander/WWW/MBChB/ImmGloss.html and Cann (2001).
Adaptive immunity: Host immune response mediated by B- and T-cells, for example, antibodies,
or cytotoxic (CD8) T lymphocytes.
Anergy (e.g., T-cell anergy): An immunologically unresponsive state in which lymphocytes are
present but not functionally active.
Antibody: Serum protein formed in response to immunization; antibodies are generally defined in
terms of their specific binding to the immunizing antigen.
Antibody-dependent, cell-mediated cytotoxicity (ADCC): A phenomenon in which target cells,
coated with antibody, are destroyed by specialized killer cells (NK cells and macrophages), which
bear receptors for the Fc portion of the coating antibody (Fc receptors). These receptors allow the
killer cells to bind to the anti-body-coated target.
Antigen: Any foreign material that is specifically bound by specific antibody or specific
lymphocytes; also used loosely to describe materials used for immunization. Antigens may also be
immunogens if they are able to trigger an immune response, or haptens if not.
Antigen-binding site: The part of an immunoglobulin molecule that binds antigen specifically.
Antigen-presenting cell (APC): A specialized type of cell, bearing cell surface class II MHC
(major histocompatibility complex) molecules, involved in processing and presentation of antigen
to inducer, or helper, T-cells. Examples: macrophage, dendritic cells.
Antigen receptor: The specific antigen-binding receptor on T- or B-lymphocytes; these receptors
are transcribed and translated from rearrangements of V genes.
Antigenic determinant: A single antigenic site or epitope on a complex antigenic molecule or
particle. 
Antigen processing: Large molecules are broken down (processed) within macrophages into
peptides and presented within the groove of MHC molecules.
Autoimmunity (autoallergy): An immune response to "self" tissues or components. Such an
immune response may have pathological consequences leading to autoimmune diseases.
B lymphocyte (B cell): The precursors of antibody-forming plasma cells; these cells carry
immunoglobulin and class II MHC (major histocompatibility complex) antigens on their surfaces.
CD3 (clone 145-2C11; used in papers II and V): antibody reacts with the 25-kDa chain of the T-cell
receptor associated CD3 complex, which is expressed on thymocytes and mature T lymphocytes of
all mouse strain tested. The cytoplasmic domain of CD3e participates in the signal transduction
event, which activates several biochemical pathways as a result of antigen recognition. Also found
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on some NK cell subsets (expression is activation dependent, e.g., antigen expression level changes
on activated cells). Such cells might be more related to T-cells than NK-cell. See also NKT-cell.
Cell-mediated cytotoxicity (CMC): Killing (lysis) of a target cell by an effector lymphocyte.
Cell-mediated immunity (CMI): Immune reaction mediated by T-cells; in contrast to humoral
immunity, which is antibody mediated. Also referred to as delayed-type hypersensitivity.
Class I and II MHC molecules: Proteins encoded by genes in the major histocompatibility
complex (q.v.). Class I molecules are designated HLA-A, B, or C. Class II molecules are designated
DP, DQ or DR.
Cytokines: Soluble substances secreted by cells, which have a variety of effects on other cells, e.g.,
interleukins.  
Cytotoxic (cytolytic) T cell: Cell that kills target cells bearing appropriate antigen within the
groove of a MHC class I molecule that is identical to that of the T cell.
Determinant: Part of the antigen molecule that binds to an antibody-combining site or to a receptor
on T-cells. 
Epitope: An alternative term for antigenic determinant.
Fluorescent antibody: An antibody coupled with a fluorescent dye, used with a fluorescence
microscope to detect antigen on cells, tissues, or microorganisms.
H-2 complex: The major histocompatibility complex situated on chromosome 17 of the mouse;
contains subregions K, I, and D.
Helper T-cells: A class of T-cells that help trigger B-cells to make antibody against thymus-
dependent antigens. Helper T-cells also help generate cytotoxic T-cells.
Humoral immunity: Any immune reaction that can be transferred with immune serum is termed
humoral immunity (as opposed to cell-mediated immunity). In general, this term refers to resistance
that results from the presence of specific antibody.
Hybridoma: A hybrid cell that results from the fusions of an antibody secreting cell with a
malignant cell; the progeny secrete antibody without stimulation and proliferate continuously both
in vivo and in vitro.
Immunecompetent: Capable of developing an immune response (possessing a normal immune
system). 
Immunodeficiency: A deficiency of immune response or a disorder classified as antibody (B cell),
cellular (T cell), combined deficiency or phagocytic dysfunction disorders.
Immunosuppression: A breakdown or inability of certain parts of the immune system to function,
thus making a person susceptible to certain diseases that they would not ordinarily develop.
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Immunosuppression may be induced by drugs or result from certain disease processes, such as HIV
or FIS-2 infections.
Innate immunity: Host immune response mediated by macrophages, microglia, dendritic cells,
mast cells and natural killer cells.
Interferon: A group of proteins having antiviral activity and capable of enhancing and modifying
the immune response.
Interleukins: Glycoproteins secreted by a variety of leukocytes that have effects on other
leukocytes.
Lymphocyte: Small cell with virtually no cytoplasm, found in blood, in all tissue, and in lymphoid
organs, such as lymph nodes, spleen, and Peyer's patches, and bears antigen-specific receptors.
Macrophage: A large phagocytic cell of the mononuclear series found within tissues. Properties
include phagocytosis, and antigen presentation to T-cells.
Major histocompatibility complex (MHC): A cluster of genes on chromosome 6 in humans,
encoding cell surface molecules that are polymorphic and that code for antigens that lead to rapid
graft rejection between members of a single species which differ at these loci. Several classes of
protein such as MHC class I and II proteins are encoded in this region. These in humans, are known
as 'Human leukocyte antigens' (HLA).
Memory: In the immune system, memory denotes an active state of immunity to a specific antigen,
such that a second encounter with that antigen leads to a larger and more rapid response.
MHC class I molecule: A molecule encoded to genes of the MHC which participates in antigen
presentation to cytotoxic T (CD8+) cells.
MHC class II molecule: A molecule encoded by genes of the MHC which participates in antigen
presentation to helper T (CD4+) cells.
MHC restriction: The ability of T lymphocytes to respond only when they 'see' the appropriate
antigen in association with "self" MHC classes I or II proteins on the antigen presenting cells.
Mitogen: A substance that stimulates the proliferation of many different clones of lymphocytes.
Monoclonal: Literally, coming from a single clone. A clone is the progeny of a single cell. In
immunology, monoclonal generally describes a preparation of antibody that is monogenous, or cells
of a single specificity.
Monocyte: Large circulating white cell, 2-10% of total white cells, phagocytic, indented nucleus.
Migrates to tissues, where it is known as a macrophage.
NK cell: Naturally occurring, large, granular, lymphocyte-like killer cells. They may play a role in
resistance to tumours and virus infection. In addition, they participate in ADCC. They do not
exhibit antigenic specificity, and their number does not increase by immunization.
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NKT-cells: A population of T-cells that share some characteristics with NK cell (see CD3). The
expression of CD3/TCR by NKT-cells suggests that they require TCR-specific recognition to be
activated. The function most characteristic of NKT-cells is the rapid production of high levels of
immunoregulatory cytokines IL-4, IFN-, and TNF following stimulation in vitro. Further, NKT-
cells exhibit potent lytic activity.
Phagocytosis: The engulfment of a particle or a microorganism by leukocytes.
Polyclonal activator: A substance that induces activation of many individual clones of either T or
B-cells. See mitogen.
Primary responses: The immune response to a first encounter with antigen. The primary response
is generally small, has a long induction phase or lag period, consists primarily of IgM antibodies,
and generates immunologic memory.
Superantigen: Molecules which short-circuit the immune system, resulting in massive activation of
T-cells, rather than the usual, carefully controlled response to foreign antigens.
Suppression: A mechanism for producing a specific state of immunologic unresponsiveness by the
induction of suppressor T-cells. This type of unresponsiveness is passively transferable by
suppressor T-cells or their soluble products.
T cell: A lymphocyte that undergoes a developmental stage in the thymus.
T-dependent antigen: An immunogen that is able to induce antibody synthesis only in the presence
of lymphokines released by helper T-cells (e.g., sheep reed blood cells (SRBC) used in the plaque-
forming cell assay for primary antibody response).
T-independent antigen: An immunogen which induces antibody synthesis in the absence of
lymphokines released by T-cells; the antibodies are generally only of the IgM isotype. 
Titre: The reciprocal of the last dilution of a titration giving a measurable effect; e.g., if the last
dilution giving significant agglutination is 1:128, the titre is 128.
Vaccination: Originally referred to immunization against smallpox with the less virulent cowpox
(vaccinia) virus; more loosely used for any immunization against a pathogen. 
 
